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Abstract 
 
 
 
 Diabetes has afflicted 8.3%, approximately 25.8 million, of the United States 
population and is the seventh leading cause of death [1].  Type I diabetes (T1D) accounts for 5 
to 10% of all diagnosed cases of diabetes in the United States [2].  If present trends continue, 
the rate of T1D incidence among children under the age of 14 will increase by 3% globally [3].  
T1D is an autoimmune disorder in which the β-cells of the pancreatic islets are destroyed, 
leading to high blood sugar.  Hyperglycemia and loss of immunological tolerance to self-
antigens are common associations of T1D [4].  Periodontal disease impacts as much as 47% of 
the U.S. population and is a significant cause for tooth loss in adults [5].  Chronic infections from 
bacterial populations that colonize the tooth root surface result in the activation of immunological 
mediators and various metabolic byproducts, such as cytokines, chemokines, and tissue-
destructive enzymes [6, 7].  Studies have demonstrated that the increased systemic 
inflammation associated with periodontal disease appears to contribute to several systemic 
diseases, particularly diabetes [8, 9], with a strong, bi-directional, relationship between diabetes 
and periodontal disease in which glycemic control is a major determinant. Improved biomarkers 
for T1D prediction are needed.   
 Cytokines serve an important part in the onset of T1D and strongly determine the 
ultimate fate of β cell destruction [10].  Such cytokines include interleukin 1 beta (IL-1β), 
interleukin 6 (IL-6), interleukin 8 (IL-8), interleukin 10 (IL-10), interferon gamma (IFN-γ), and 
tumor necrosis factor alpha (TNF-α).  Th1 cytokines such as IL-1β, IFN-γ, and TNF-α have been 
demonstrated to induce pancreatic β-cell apoptosis.  Matrix metalloproteinases (MMPs) have 
been demonstrated to participate in the pathogenesis of periodontitis.  Hence, the measurement 
 xi 
of these inflammatory cytokines and MMPs may serve as a marker for the onset or progression 
of T1D and glycemic control.  There have been no previous studies describing the distribution of 
salivary biomarkers of inflammation in T1D.  Saliva represents a suitable bioreservoir for 
cytokines and can be collected noninvasively with very little to no stress upon the donor allowing 
for multiple collections if needed and it is easy to collect, store, and transport [11], however 
there are circadian patterns that must be accounted for.  Therefore, we measured the levels of 
cytokines and MMPs in the saliva of T1D patients, characterized diurnal patterns of salivary 
cytokines in healthy subjects, and explored sources of inflammation to increase our 
understanding of salivary biomarkers of inflammation as a prediction of the progression of T1D 
and gum health and glycemic control. 
 This work demonstrated that specific salivary inflammatory markers - MMP-8, MMP-9, 
and TNF-α - in T1D subjects are associated with decreased glycemic control.  Diurnal patterns 
of salivary proteins must be accounted for upon collection due to the unique rhythms of cytokine 
expression within each individual.  Upon glucose stimulation, pro-inflammatory (Th2) cytokines, 
such as IFN-γ and IL-13, tend to decrease, whereas anti-inflammatory (Th1) cytokines, such as 
IL-10, tend to increase.  Hyperglycemic conditions may promote an anti-inflammatory profile of 
human submandibular gland cells. 
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Chapter 1: Introduction & Background 
 
 
Type 1 Diabetes 
Diabetes mellitus, a Greek derived phrase from diabainein meaning “a siphon” and 
mellitus meaning “like honey”, is a metabolic disease characterized by defective insulin 
secretion and/or insulin action leading to hyperglycemia [12].  The word “diabetes” was derived 
from Araetus of Cappodocia (81-133 AD) and later “mellitus” was coined in 1675 by Thomas 
Willis after discovering the sweetness of urine and blood in diabetic patients [13].  Insulin is a 
hormone responsible for transporting glucose from the bloodstream to the body’s cells for 
energy.  Inadequate insulin action results from a combination of impaired secretion of insulin 
from β cells of the pancreas and/or weakened tissue responses to insulin [12].  Diabetes is 
classified into three different types: Type 1 diabetes (T1D), Type 2 diabetes (T2D), and 
gestational diabetes.  T1D is defined by a destruction of pancreatic β cells resulting in a 
complete failure of insulin production and is most common in younger individuals, but it can 
occur at any age.  T2D originates with insulin resistance and an inadequate insulin secretory 
response, nevertheless the pancreas is still capable of producing little insulin.  Gestational 
diabetes mellitus (GDM) is acquired by approximately 4% of all United States pregnancies and 
results from any form of glucose intolerance with onset of pregnancy, creating a risk for mothers 
developing T2D [14].   
There are environmental influences, occurring early in life either in utero or infancy, that 
have an affect towards the onset of β cell autoimmunity [15].  Immune system development and 
the turnover of pancreatic cells could contribute towards pathogenic events.  A precipitating 
event occurs, whether it be a genetic predisposition, infectious agents, or diet that triggers the 
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ultimate detrimental cascade of β cell decline.  Islet autoantibodies (anti-β cell autoantibodies) 
arise forming a dysfunctional immune response followed by (depending on the individual, 
months or years later) glucose intolerance (hyperglycemia) and altered insulin secretion [15].  
For unknown explanations, some individuals expressing these autoantibodies do not develop 
overt diabetes.  Lastly, the C-peptide levels gradually decrease into absence, though some 
individuals produce low C-peptide levels long after onset [15].  This complete timeline of T1D is 
modeled in Figure 1. 
Diabetes has afflicted 8.3%, approximately 25.8 million, of the United States population 
and is the seventh leading cause of death [1].  T1D accounts for 5 to 10% of all diagnosed 
cases of diabetes in the United States [2].  If present trends continue, the rate of T1D incidence 
among children under the age of 14 will increase by 3% globally [16].  Diabetics are at an 
increased risk of cardiovascular disease, renal failure, blindness and amputation, leading to a 
decreased quality of life and, quite often, a premature death.  Given the importance of T1D 
management for overall improved clinical outcome, additional measures are needed to evaluate 
glycemic control and elucidate the contributing immunological mechanisms.  With the rate of 
diagnosis of T1D globally increasing, the search for reliable biomarker and better understanding 
of the onset of the T1D is critical. 
 
Potential Triggers of T1D 
Genetics 
There are many proposed factors that can contribute to the progression of T1D.  Several 
loci are considered to increase the risk of T1D, with the most important genes being located in 
the human leukocyte antigen (HLA) class II locus on chromosome 6, a locus involved in the 
determination of specific αβ T cells of the immune system [17, 18].  The HLA locus also 
contains genes that code for major histocompatibility complex (MHC) molecules that are 
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responsible for specific polymorphisms of the DQ and DR forms of MHC Class II molecules 
related to the genetic predisposition of T1D involving the HLA locus [19]. 
 
The theory that T1D is an immune mediated disease is supported by the fact that other 
genetic loci primarily expressed in cells modulating the immune system, such as gene coding 
regions for interleukin-2 receptor α, protein tyrosine phosphatase non-receptor type 22, and 
cytotoxic T lymphocyte antigen 4, have been found to be associated with increased risk of T1D 
[18].  Recently, there is increasing evidence that over 60% of T1D candidate genes, most of 
which are modulated by pro-inflammatory cytokines, are expressed in human pancreatic islets 
[20].  Genome-wide association studies (GWAS) screen single nucleotide polymorphisms 
(SNPs) to investigate the association of disease and genetic variants and a genetic variant 
located near the insulin gene, IRS1 (coding for the insulin receptor substrate-1), has been 
recognized to be associated with T2D, hyperglycemia, and insulin resistance [21, 22].  There 
are additional discoveries of an association of T1D with insulin (i.e. IDDM2 locus) and other β 
cell molecules (i.e. GLIS3) that may affect β cell function and antigen presentation [18, 19].  The 
monozygotic concordance rate of T1D is >50% and there is a ~6% chance of developing the 
disease if a sibling is affected [18].  Hence, environmental factors must also play a role in 
genetic susceptibility of the disease. 
 
Infectious Agents 
Autoimmunity is thought to be triggered by some environmental factor(s) acting on an 
already genetically predisposed immune system [23, 24] .  Some of these environmental factors 
of T1D include: infectious agents, such as viruses and enteroviruses, diet, psychosocial 
environment, and even perinatal factors.  There are several theories of the mechanistic 
breakdown of viruses and their influence on islet autoimmunity and β cell decay.  Many studies 
performed in animal models have demonstrated that infectious agents can trigger islet 
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autoimmunity through a variety of ways, either through exocrine or endocrine pancreatic tissue, 
molecular mimicry where antigens from infectious agents share epitopes with islet antigens, or 
activation of innate immunity [24].  It is known that innate nonspecific immune pathways, 
including inflammation and Toll-like receptor (TLR) signaling, contribute to specific adaptive 
responses, but these pathways may also assist in islet autoimmunity [25].  One study revealed 
that expression of certain TLRs in T1D patients were more elevated than in healthy individuals 
[26].  Components of viruses are considered to be robust activators of TLR signaling, yet the 
mechanisms involved remain elusive [26]. 
While it is difficult to determine the mechanisms involved with islet autoimmunity, 
recognizing relevant specific infections will elucidate the connections between infection and islet 
autoimmunity [24].  In one study, children whom contracted congenital rubella virus were found 
to have acquired T1D at a rate of 12% [24, 27].  Enteroviruses have been studied, most 
commonly Coxsackie B4, due to the fact that they infect the pancreas and tissues in contact 
with the gut-associated lymphoid.  It is theorized that additional exposure events may accelerate 
the progressive downfall of β cell function once autoimmunity has been initiated and islet 
autoantibodies are present [24].  The relation between enteroviruses and T1D, however, is 
inconclusive despite the many years of research [24].   
There are numerous studies conducted to examine the impact of viral infections on T1D.  
TEDDY (The Environmental Determinants of Diabetes in the Young), is an ongoing, 
international longitudinal study that enrolls children who are a first-degree relative of someone 
with T1D to investigate the infectious agents, dietary factors, or other environmental agents that 
lead to the development of T1D and is striving to address the incomprehensive etiology of the 
disease [28].  Current TEDDY data from Finland suggest a relationship between enterovirus 
infections and the development of islet autoantibodies [29].  Another study, The Diabetes and 
Autoimmunity Study in the Young (DAISY), investigates genetically predisposed children and 
their chances of developing T1D from environmental factors [30, 31].  Out of the children who 
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developed islet autoimmunity, approximately 36% progressed to T1D, due to viral RNA present 
in their blood [31].  In addition to viral-induced T1D, many studies have determined a link 
between diet and the progression of the disease [23, 32-34]. 
 
Diet 
The first signs of β cell autoimmunity may occur during the first year of life, suggesting 
environmental risk factors are the cause.  There are several controversial studies that suggest 
breastfeeding as well as early introduction of cow’s milk proteins and cereal may or may not 
have an impact on the development of T1D [23].  Interestingly, too early of an introduction of 
fruits, berries, and roots may present an increased risk of β cell autoimmunity.  Islet antibodies 
were found in blood samples from HLA-DQB1-conferred young children aged < 4 months who 
were introduced to fruits, berries, and/or roots [34].  Other studies have shown an association 
with vitamin D supplementation [23] and a decreased diabetes risk, whereas cod liver oil 
(omega-3 polyunsaturated fatty acid) intake [32], and low levels of vitamin E [33] have been 
associated with an increased diabetes risk.  Both TEDDY and DAISY studies are investigating 
the role diet plays on the progression of T1D through analysis of food introductions during early 
childhood years [32, 35, 36].  TEDDY is assessing infant and childhood diet through the 
collection of toenail clippings, plasma, and erythrocytes for potential dietary biomarker analysis 
and food diaries at 3-month intervals during the first year of life and biannually thereafter [36].  
This will assist in uncovering the cause of T1D, yet the mechanisms behind the disease need 
further elucidation. 
 
Immunological Mechanism 
The immune system is divided into two components: the innate immune system 
(unspecified immune cells such as neutrophils, monocytes, natural killer (NK) cells) that is the 
first line of defense and attacks foreign antigens and the adaptive immune system (antigen-
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specific immune cells such as lymphocytes T and B cells) that provides protection against 
additional exposure to the same pathogen [37].  T and B lymphocytes are responsible for 
providing protection to the adaptive immunity through utilization of clonal receptors.  Activated 
immune cells destruct β cells through mechanisms involving perforins, granzymes, Fas/FasL, 
reactive oxygen and nitrogen species, and pro-inflammatory cytokines [19].  These cytokines 
will then bind to receptors on β cells activating MAP-kinases and transcription factors, STAT1 
and NFκ-B, ultimately leading to apoptosis [19]. 
T1D is described as a T cell mediated autoimmune disease that is initiated by the 
processing of self-antigens by antigen presenting cells to auto-reactive CD4+ T cells in the 
pancreatic lymph nodes.  Thereby, a pro-inflammatory detrimental cascade is initiated, resulting 
in the generation of autoantibody producing B cells, pro-inflammatory cytokine release, and 
activated cytotoxic CD8+ T cells [18, 38].  This immunological response of T1D is outlined in 
Figure 2.   
There is supporting evidence that cellular immune responses contribute to the 
destruction of β cells: presence of T cells in insulitis, detection of circulating autoreactive T cells, 
and disease progression is delayed by immunosuppressive drugs targeting T cells [17, 39].  
CD8+ cell accumulation and MHC class I hyperexpression have been located in the pancreatic 
islets of donor patients with early onset and established T1D [40].  It is debated whether islet-
autoreactive T lymphocytes are activated initially.  MHC II molecules are believed to be involved 
in the activation of T cells through their presentation of autoantigenic determinants to self-
reactive T cells [17, 18].  Nonetheless, there are many controversial theories on how the 
immune system provokes β cell death and whether or not it occurs through apoptosis or 
necrosis pathways.  One method of β cell apoptosis is through the production of perforins and 
granzymes. 
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Perforins and Granzymes in β Cell Destruction 
Both perforins and granzymes are located within lysosomal granules of natural killer 
(NK) cells and cytotoxic lymphocytes.  Perforins are cytolytic proteins that function 
synergistically with granzymes, serine proteases that possess a strong preference for cleaving 
after specific aspartate sites [41].  Although the synergistic mechanism between the two is 
poorly understood, there is evidence that granzyme may enter cells solo, but requires perforin to 
mediate apoptosis [41].  One proposed theory is that activated CD8+ T cells release cytotoxic 
molecules, such as perforins and granzymes, which damage cell membranes.  This destruction 
is particularly caused by perforin creating holes in the β cell membranes, allowing osmotic death 
and permitting protease granzyme B to enter, release cytochrome c, and activate caspases [41, 
42].  This theory has been contested by a study that found non-obese diabetic (NOD) mice with 
perforin-deficient T cell receptors still developed diabetes more frequently than those with 
perforin-competence, however diabetes developed in a Fas-dependent manner [43].  This 
indicates that although perforins and granzymes play a minor role in β cell death, it is likely that 
cytokines are the major players.   
 
Fas/FasL in β Cell Destruction 
One of the more critical signaling routes of β-cell apoptosis is through the FAS ligand 
(FASL), which is located on activated CD4+ and CD8+ T cells [42, 43].  Several studies have 
shown that FASL is expressed in both human [44] and NOD mice [45] islets upon induction of 
cytokines.  FASL will bind to the FAS receptor on β cells triggering the release of cytokines, the 
activation of caspase 8, followed by the activation of caspase 3, initiating permeabilization of 
mitochondrial membranes, ultimately leading to the fate of β cell apoptosis [42].  This process is 
outlined in Figure 3.  Some studies have claimed FAS-deficient NOD mice were resistant to the 
progression of diabetes.  Such studies were disproved by the event that diabetes is prevented 
via apoptosis of the adoptive transferred lymphocytes elicited by abnormal FASL expressing 
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lymphoid cells in FAS-deficient NOD mice [43].  Additionally, β cell destruction from Fas 
expression has been found to be nitric oxide-mediated in insulin-dependent diabetes [44].   
 
Nitric Oxide in β Cell Destruction 
Activated macrophages produce free radicals and oxidants such as superoxide, hydrogen 
peroxide, hydroxyl radicals, peroxynitrate, and nitric oxide (NO) [46].  Accordingly, free radicals,  
primarily NO, have been implicated as one of the key mediators of -cell destruction [47, 48].  
There is an extensive review of the role of NO in cytokine-mediated β cell destruction [41].  
Cytokines, such as IL-1β, activate inducible nitric oxide synthase (iNOS) in macrophages, 
generating high concentrations of NO via nuclear factors, such as nuclear factor κ B (NF-κB) 
[41] as shown in Figure 3.  NO will destroy β cells through a variety of methods, including 1) the 
inactivation of Krebs cycle enzymes preventing mitochondrial glucose oxidation and ATP 
formation, 2) the damage of DNA strands leading to activation of tumor suppressor proteins 
inducing apoptosis, or 3) the role of a redox mediator in cytokine-induced apoptosis [43]. 
 
T1D and Cytokine Involvement in Inflammatory Response 
Cytokines are soluble molecules that are produced by many different cells in a highly 
regulated fashion that act at picomolar to nanomolar concentrations on cytokine receptors 
expressed by target cells [49].  Because cytokines are regulators as well as mediators of the 
immune response, it is evident that they may play a key role in the pathogenesis of T1D.  It is 
believed that the initiation of the autoimmune response in T1D results from a disorder of 
immunoregulation [50].   
Type 1 cytokines- IL-2, IFN-γ, TNF-α, and TNF-β- initiate a cascade of 
immune/inflammatory processes in the islet (insulitis), culminating in β-cell destruction [46] 
(Figure 3).  Type 2 cytokines- IL-4, IL-6, IL-10, and IL-13- are part of the humoral immune 
response and assist in downregulating the inflammatory actions of Th1 cells [51].  While T 
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helper 1 (Th1) cells secrete Th1 cytokines to play a pathogenic role, T helper 2 cells (Th2) 
secrete Th2 cytokines to mediate protection from inflammatory disease, such as T1D. 
It has been shown in non-obese diabetic (NOD) mice and bio-breeding (BB) rats that 
cytokines are expressed in pancreatic insulitis lesions [52].  The inflammatory infiltrate of the 
pancreatic islets consist mainly of CD4+ Th1 helper T cells, CD8+ T cells, dendritic cells, 
macrophages, and natural killer (NK) cells [53].  T1D is believed to develop when one or 
another immunoregulatory mechanism fails, allowing β-cell reactive T cells to become activated, 
reactive to β-cell antigens and islet cell antibodies produced by B cells, and expand clonally [46, 
50, 54].  This arises a cascade of immune/inﬂammatory processes in the islet (insulitis), leading 
to the ultimate fate of β-cell destruction [46].   
Macrophages and dendritic cells migrate towards pancreatic islets, where they present β 
cell-specific antigens that initiate the differentiation of Th0 CD4+ T cells into T helper (Th) CD4+ 
cells [42].  T helper CD4+ cells may differentiate into subsets of effector cells that produce 
distinct sets of cytokines and perform different functions [55].  These subsets, Th1 and Th2 
cells, may be distinguished not only by the cytokines they produce, but also by the cytokine 
receptors and adhesion molecules they express.  For example, Th1 cells produce high amounts 
of IFN-γ and IL-12, which activate macrophage and CD8+ T cells, respectively, that interact 
specifically with β-cells and destroy them [55].  Additionally, cytokine release induces migration 
of activated CD8+ cytotoxic T cells to islets where β cells are stimulated to release even more 
cytokines and chemokines, which will lead to further immune activation [42].   
Some or all of these mechanisms may be responsible for the end stage destruction of 
the insulin-producing pancreatic islet -cells.  Discovering the molecular mechanisms of β-cell 
destruction is crucial in understanding the immunopathogenesis of T1D and may provide novel 
insights into preventative and therapeutic interventions.  Specific inflammatory markers, such as 
TNF-α, MMP-8, and MMP-9, of T1D subjects are associated with poor glycemic control [56].  
Hyperglycemia is known to induce an increase in C-reactive protein (CRP) levels (a clinically 
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relevant marker of inflammation) and adiponectin levels, which in turn lead to increased 
inflammatory markers [57].  Yet, certain cytokines and chemokines have yet to be evaluated to 
determine their role in inflammation, glycemic control, and T1D. 
 
IL-1β and T1D 
IL-1β is a Th1 type cytokine that is produced by activated macrophages and neutrophils 
and its major function is to mediate and regulate innate immune responses [49].  In T1D, IL-1β 
has been shown to be cytotoxic to pancreatic β-cells in vitro through the stimulation of 
increasing nitric oxide, prostaglandins, and ceramide in these cells [58].  In addition, electron 
microscopy exhibits that IL-1β has a selective β-cell toxic effect in which islet integrity is 
destroyed and glucose-stimulated insulin release is almost completely inhibited [59].  It is 
believed that IL-1β, as well as TNF-α, activates the transcription factor, nuclear factor-κB (NF-
κB), which induces β-cell apoptosis [60]. 
 
TNF-α and T1D 
TNF-α is a Th1 type cytokine that is produced mainly by activated macrophages, NK 
cells, mast cells, and Th1 cells and may induce macrophage production of IL-1 and IL-6, but its 
primary function is to recruit neutrophils and monocytes to infection sites and activate them 
upon their arrival [49].  Evidence that TNF-α plays a role in T1D development is supported by 
several studies.  One study demonstrated a protection against diabetes in transgenic NOD mice 
expressing the TNF receptor to become neutralized of TNF [43].  Another study verified when 
the TNF-α receptor 1 is blocked in NOD mice, the onset and incidence of T1D is delayed [61].  
Additionally, TNF-α (and IL-6) secretion from adipose tissue is associated with obesity and 
insulin resistance [62].  Altogether, these findings indicate that TNF-α is a strong candidate of 
initiating the pathogenesis of T1D. 
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IFN-γ and T1D 
IFN-γ is a Th1 type cytokine that activates cell-mediated immunity, such as cytotoxic and 
inﬂammatory responses mediated by T-cells, natural killer (NK) cells and macrophages [49].  
Evidence for IFN-γ being a β-cell cytotoxic cytokine in T1D derives from the findings that 
transgenic expression of IFN-γ by β-cells in normal mice leads to an autoimmune, lymphocyte-
dependent infiltration of the islets by mononuclear cells (insulitis), β-cell destruction, and T1D 
[63, 64].  Further supporting this role, diabetes is prevented by anti-IFN-γ antibodies in BB rats 
and by IFN-γ receptor α-chain mutations or IFN-γ deficiency in NOD mice [43]. 
 
IL-6 and T1D 
IL-6 is produced by macrophages, endothelial cells, and activated T cells in response to 
IL-1 and TNF-α [49].  IL-6 activates Th2 cytokine production in CD4+ T lymphocytes and is also 
an important factor in the synthesis of C-reactive protein, which is increased in inflammatory 
diseases [65].  A previous study concluded that IL-6 impacts glucose oxidation by altering 
insulin secretion in rat pancreatic islets and discovered a possible role of B cell suppression and 
destruction during diabetes [66].  A recent study indicates that changes in IL-6 levels contribute 
to the change in insulin resistance over time in T1D patients [67].    
 
IL-8 and T1D 
IL-8 recruits neutrophils and is produced by macrophages, which amplify T cell 
responses and may cause direct β-cell dysfunction [38].  IL-8 has been thought to be a 
chemokine, which is produced either by cells in inflamed tissue or sites of antigen exposure, 
which induces adaptive immunity by recruiting leukocytes to inflammation sites [49].  IL-8 is 
considered to be one of the most potent chemokines present and previous studies have 
demonstrated that IL-8 levels are increased in both T1D and T2D through the promotion of a 
pro-inflammatory state in monocytes [68, 69]. 
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IL-10 and T1D 
IL-10 is a Th2 cytokine that inhibits cytokine synthesis (particularly Th1 cytokines and IL-
12), activated macrophages, dendritic cells, and controls the innate immunity.  The concept that 
expression of Th2 cytokines (IL-4 and IL-10) in islets protects against β-cell destructive insulitis 
is supported by studies in which increased numbers of IL-4 and IL-10-producing cells were 
found in islets of NOD mice protected from diabetes development by various treatments, such 
as oral administration of insulin [46].  Further supporting this role, IL-10 has been shown to 
significantly reduce the onset of T1D in NOD mice via its inhibition of IFN-γ synthesis by Th1 
cells [70].  Altogether, these data suggest a potential therapeutic role for T1D. 
 
Stress Pathways and Cytokines 
Inflammatory mediators released during disease activate several intracellular pathways, 
including the NF-κB and MAPK pathways.  NF-κB is comprised of five members that are 
normally inactive in the cytoplasm through the binding of inhibitory IκB proteins.  Pro-
inflammatory cytokines, such as IL-1β, TNF-α, and IFN-γ, activate signaling pathways, including 
p38 MAPK and NF-κB that direct pancreatic β-cell death and dysfunction [71].  IL-1β activates 
the interleukin cell surface receptors to recruit receptor adaptor proteins, leading to signaling of 
IκB kinases (IKKs) [71].  Subsequently, IκB proteins are phosphorylated by IKKs, which 
stimulate the degradation of IκB proteins, and release of NF-κB proteins to translocate into the 
nucleus from the cytoplasm.  Various NF-κB subunits are now permitted to hetero- and homo-
dimerize inside the nucleus to transactivate an assortment of genes  involved in inflammatory 
responses that rise to tissue dysfunction and cell death [71].  One study suggested IL-1β 
induces degradation of IKKβ via the proteasome and TRAF6, TAK1, and JNK dependent 
signaling pathways in insulin-producing INS-1E cells [60].  TNF-α is believed to utilize a different 
strategy by activating the IKK complex (containing both IKKα and IKKβ) via TRAF2 and receptor 
interacting serine/threonine protein kinase (RIPK) to induce β-cell death [42, 60].  IFN-γ may 
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induce phosphorylation of the Janus kinase (JAK) family, leading to the phosphorylation and 
recruitment of STAT1 [42].  Once STAT1 is phosphorylated, it will homodimerize and transport 
into the nucleus where it will activate apoptosis-inducing genes [42].   
Several studies have indicated that p38 MAPK promotes pro-inflammatory cytokine 
production, yet the molecular mechanism is poorly understood [72, 73].  The mitogen-activated 
protein kinase (MAPK) signal transduction pathway plays a significant role in the recruitment of 
leukocytes to sites of inflammation.  This stimulation of leukocytes by pro-inflammatory 
cytokines leads to the activation of p38 MAPK [74].  There are three members of the MAPK 
pathway: 1) ERK1 & 2, which is activated by chemoattractants and growth factors, 2) c-Jun N-
terminal kinase (JNK), and 3) p38 MAPK, which are stress- and cytokine-activated [75].  MAPK 
members are regulated by phosphorylation of tyrosine and threonine residues [76].  Prior 
reports have indicated that IL-6 production is increased from salivary gland epithelial cells 
during Primary Sjörgren’s syndrome (SS) via activation of intracellular signaling cascades, 
including the mitogen-activated protein kinase (MAPK) and NF-κB pathways. In a particular 
study, pharmacological inhibition of p38 MAPK or NF-κB, but not JNK, significantly suppressed 
palmitate-induced IL-6 secretion in human parotid gland epithelial cells, suggesting that IL-6 
secretion is induced through activation of said pathways [77]. 
 
Circadian Rhythms & Inflammation 
 Circadian, or diurnal, rhythms are biological processes over a 24 hour time period in 
organisms ranging from bacteria to humans, thus creating time of day-dependent variations 
[78]. There are several factors that influence the circadian rhythm of the body: light, 
melatonin/hormones, cognitive functions, mood, and core body temperature to name a few.  In 
mammals, the master regulator of circadian rhythms is the suprachiasmatic nucleus (SCN) 
located in a tiny region of the hypothalamus, which regulates oscillations of clock genes in 
peripheral tissues [78, 79].  The circadian molecular clock consists of a network of 
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transcriptional-translational feedback loops that regulate the 24 hour expressions of clock 
proteins.  Transcription factors, BMAL1 and CLOCK, heterodimerize and transcribe Period 
(murine PER1, PER2, and PER3) and Cryptochrome (CRY1 and CRY2) genes, which in turn 
dimerize and translocate back into the nucleus, where they interact with the CLOCK:BMAL1 
complex [79].  These molecular mechanisms have been examined primarily with mice.  Little is 
known on the impact of altered circadian rhythms in oral inflammation in humans. 
Local circadian clocks may be present in the liver, heart, skin, kidney, and cultured cell 
lines.  It has been shown that in vitro culture conditions, cortisol-mediated cytokine secretion 
rhythms exist, suggesting a local macrophage-intrinsic clock [78].  Interestingly enough, one 
study examined human submandibular gland (HSG) cells and suggested internal circadian 
rhythms derived from the transcription factor, BMAL1, and its repressor, REV-ERBα [80].  This 
local circadian clock is utilized to regulate the type, amount, and content of saliva.  Melatonin is 
well known to control phase shifts in circadian rhythms, is released into the saliva, and 
increases in response to periodontal inflammation [81, 82].  In addition to melatonin and cortisol 
being the primary regulators of circadian clocks and diurnal rhythms of cytokines, contradicting 
studies claim glucocorticoids may/may not play a role [83].  There is evidence of a connection to 
the progression of diabetes and the ablation of certain clock genes in mice that led to abnormal 
glucose tolerance, impaired insulin secretion, and altered islet gene expression [84].  Further 
research needs to be conducted to determine the impact of circadian rhythms and oral 
inflammation. 
The recent discovery of clock genes in the gastrointestinal tract play a critical role in the 
progression of inflammation by impacting intestinal epithelial cell permeability [85].  Although it 
is well known that clock genes are one of the key regulators of cell functions, the mechanisms of 
how clock genes contribute to the regulation of cell proliferation during disease have yet to be 
elucidated [86].  Inflammatory mediators, such as TNF-α, can also suppress the expression of 
the period clock genes in murine fibroblasts in vitro and in vivo in TNF-α-infused mice [87].  
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Previous reports have supported the complex relationship of circadian rhythms and the 
regulation of the immune system, including CD4+ T cells, eosinophils, and macrophages by 
clock gene transcription [86].  Nonetheless, additional research is needed to gain a full 
comprehension of clock gene expression within the immune system.  Inflammation can be 
triggered through a poor management of glycemic control and subsequent hyperglycemia. 
 
Hyperglycemia and Glycemic Control  
Hyperglycemia is a classic manifestation of T1D and if managed poorly, can lead to 
cardiovascular and periodontal disease [88].  Previous studies have demonstrated there is an 
association between biomarkers of inflammation and glycemic control in type 1 diabetics [89, 
90].  Hyperglycemia leads to the non-enzymatic glycation of sugars that lead to the formation of 
Schiff bases and Amadori products that produce advanced glycation end products (AGEs) [91].  
These AGEs interact with their receptors on monocytes and stimulate the inflammatory process 
[92].  This process is outlined in more detail in Figure 4.  HbA1c has been associated with 
increased levels of systemic inflammation [91], and inflammation in turn has also been 
associated with vascular complications of diabetes [92].  In addition, the pathogenic effect of 
hyperglycemia has been shown to activate stress-sensitive pathways, which secrete 
inflammatory cytokines [93].  There are no established noninvasive methods for glycemic 
control.   
Human hemolysate contains several minor components designated HbA1a, HbA1b, 
HbA1c, which are post-translational modifications of the major hemoglobin component A0 [94].  
HbA1c is the direct reaction of hemoglobin with glucose.  HbA1c is a test that measures 
glycosylated hemoglobin over a three month period, which is the approximate lifetime of an 
erythrocyte. The normal HbA1c levels are between 4-5.6%, whereas diabetic levels are 6.5% or 
higher [95].  A high HbA1c result has been associated with increased levels of inflammation and 
vascular complications of diabetes [95].   
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There is no real non-invasive measure of glycemic control.  Based on the guidelines 
from the American Diabetes Association (ADA), T1D diabetics should monitor their glucose 
levels at least four times a day.  Studies have demonstrated that continual self-monitoring of 
blood glucose (SMBG) results in better clinical outcomes and thereby reducing all-cause 
mortality such as those associated with myocardial infarction. In addition, SMBG appears to 
result in significant savings from a health economics standpoint.  SMBG allows T1D patients to 
evaluate their individual response to therapy using a glucose meter and frequency is dictated by 
each patient’s needs and goals.  Effective clinical intervention to avoid the glycemic peaks and 
valleys typical of T1D management would greatly reduce the incidence of morbidity and 
mortality.  Many patients with T1 or T2D associate SMBG with pain, frustration, and a continual 
demoralizing reminder that they have diabetes.  Therefore, it is critical to develop alternative 
strategies for evaluation of patient compliance for management of T1D.   
 
IL-13 and Hyperglycemia 
 IL-13 is a Th2 cytokine that mediates macrophage activation and inhibits inflammatory 
cytokine production.  IL-13 is considered a critical mediator of mucus secretion in the lungs and 
in the regulation of cell-mediated immunity and tissue fibrosis [96].  In diabetes, IL-13 regulates 
hepatic glucose production via its receptor, IL-13rα1, and the STAT3 signaling pathway in the 
liver [97].  It remains unclear what regulates the IL-13 (and IL-4) receptor expression and how 
that affects functional activity of IL-13.   
 
IL-4 and Hyperglycemia 
 IL-4 is a Th2 cytokine and is functionally related to IL-13; it too inhibits inflammatory 
cytokine production.  Studies have shown a prevention of diabetes in vivo when IL-4 is 
administered to NOD mice and in vitro when IL-4 is transgenically expressed in pancreatic β 
cells [51].  In another study analyzing plasma from 22 children with T1D with and without 
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hyperglycemia, it was concluded that cytokines IL-1α, IL-6, and IL-4 were highly elevated during 
and remained elevated after correction of hyperglycemia [98]. 
 
IL-2 and Hyperglycemia 
 IL-2 is a Th1 cytokine produced by CD4+ T cells known to support regulatory T cell 
survival, whose function is to regulate pathogenic autoimmune responses in T1D [99].  In 
pokeweed mitogen-stimulated (activates T and B lymphocytes) human peripheral blood 
mononuclear cells, endogenous production of IL-2 (IL-6 and IL-10 as well) is inhibited by a 
suppressed immune response from high glucose-induced TGF-β production [100].  One study 
observed that as periodontal health worsened in type 1 diabetics, levels of IL-2 decreased, 
possibly due to periodontopathic bacteria metabolic products [101].  There is limited information 
on IL-2 secretion and its impact on hyperglycemia.  Therefore, analysis of its role in 
hyperglycemic conditions in salivary gland cells may provide useful insight into understanding 
IL-2 expression in diabetes and/or periodontitis. 
 
Saliva Production and Secretion 
Saliva is a clear, slightly acidic mucoserous exocrine derived liquid containing a mixture 
of secretions from major and minor salivary glands and from gingival crevicular fluid (GCF) [102, 
103].  Saliva is composed of 99% water, containing electrolytes (i.e. sodium, potassium, 
chloride, and phosphate), enzymes, immunoglobins, glycoproteins, and small amounts of 
albumin [101].  There are three major glands involved in saliva secretion: parotid, 
submandibular, and sublingual.  The parotid gland is the largest and secretes serous saliva, 
while the others secrete saliva containing mucous [104].  The submandibular gland contains 
both serous and mucous cells.  The sublingual gland consists mainly of mucous cells with very 
few serous cells.  The localization of these glands can be depicted in Figure 5.  Some 
biomolecules, such as steroid hormones and/or immunoglobulin A (IgA), enter the saliva from 
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blood by passive diffusion of lipophilic molecules, ultrafiltration, or through active transport of 
proteins via ligand-receptor binding [11].  These processes are modeled in Figure 6.  Serum 
components can be identified in the saliva, however the components that are produced locally 
by the salivary glands may not be detected in plasma [105].  In addition, it has been shown that 
amines and peptides, such as melatonin and insulin, enter the saliva through these methods 
and exhibit an excellent correlation between saliva and blood concentrations [106].  Because 
saliva contains serum constituents and certain hormones that correlate to blood concentrations, 
it is a favorable diagnostic of systemic diseases. 
 
Saliva as a Diagnostic Fluid 
There has been an increase of interest in using saliva as a diagnostic medium over the 
past 10 years [11].  However, the use of saliva as a measurement for biomarkers in T1D has not 
yet been established.  There are several reasons why saliva is advantageous in comparison to 
serum: it can be collected noninvasively with very little to no stress upon the donor allowing for 
multiple collections if needed, it does not require training or expertise for collection, and it is 
easy to collect, store, and transport [11].  Saliva provides a more accurate representation of the 
individual’s health and well-being at the moment of collection.  This is due to the fact that the 
salivary glands are exocrine glands that produce proteins indicative of one’s health.  Steroid 
hormones, proteins, and cytokines make their way into the saliva from the capillaries via active 
transport, ultrafiltration, or diffusion [107] as shown in Figure 6.  Additionally, larger proteins can 
be transported into the saliva from the gum tissues and gingival fluid. 
Studies have shown differential salivary protein expression in T1D adults and children in 
comparison to non-diabetics [108, 109].  More recently, a study described that peptidome data 
not only support a diabetes-related higher susceptibility of salivary proteins to proteolysis, but 
also evidenced an increased content of some specific protein fragments known to be related 
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with bacterial attachment and the accumulation of phosphopeptides involved in tooth protection 
[110].   
Although it is quite difficult to quantify the inflammatory burden presented by diabetes 
and periodontitis, there have been several attempts collecting and analyzing GCF to assess the 
inflammatory response [111].  However, there are limitations of the collection of GCF since 
there is a need to collect multiple times throughout the dentition and this collection process only 
occurs at selected sites of the crevice of each tooth [111].  Collection of whole saliva includes 
GCF, sloughed epithelial cells, bacteria, and other constituents derived from the salivary glands 
rendering a wide assessment of the oral inflammatory burden [111]. 
The one disadvantage to using saliva as a diagnostic fluid is that the diurnal/circadian 
variations of cytokines and other biomolecules present in the saliva do not always reflect the 
concentrations of these molecules in serum [11].  High sensitive assays have been developed 
and are being improved to enhance sensitivity.  Once the diurnal patterns of salivary 
components are identified, a better understanding towards salivary diagnostics can be 
achieved.  Previous studies have shown that the saliva test for antibodies to HIV, which is the 
best known of the saliva-based diagnostic tools, approaches the sensitivity and specificity of a 
blood test [11].  
 
Periodontal Disease and Diabetes 
Periodontal disease is an inflammatory disease derived from pathogenic bacteria, such 
as Porphyromonas gingivalis (P. gingivalis), Prevotella intermedia, or Aggregatibacter 
actinomycetemcomitans, in the biofilm and may arise from genetic, developmental, traumatic, or 
inflammatory origins [112, 113].  Gingivitis is the mildest form of periodontal disease and results 
from the accumulation of bacterial biofilm on teeth flanking the gingiva, or gums [113].  
Periodontitis destructs the underlying support structure of the teeth through the deterioration of 
connective tissue and reduction in alveolar bone [113].   
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Periodontal disease affects as much as 47% of the U.S. population and is a significant 
cause for tooth loss in adults [5].  Periodontal (gum) disease is more common in people with 
diabetes.  Among young adults, those with diabetes have about twice the risk of those without 
diabetes [1].  Adults with poor glycemic control (HbA1c > 9%) were 2.9 times more likely to have 
severe periodontitis than those without diabetes [1].  Studies have demonstrated that the 
increased systemic inflammation associated with periodontal disease appears to contribute to 
several systemic diseases, particularly diabetes, with a strong, bi-directional, relationship 
between diabetes and periodontal disease in which glycemic control is a major determinant.  
Periodontitis is driven by bacterial infections that colonize the tooth root surface [6].  Due 
to this pathogenic event, immunological mediators are activated and various metabolic 
byproducts such as cytokines, chemokines, and tissue-destructive enzymes are released [7].  
Spillover of these immunological mediators into the general circulation is thought to play a role 
in the development and exacerbation of systemic diseases, particularly diabetes, where a bi-
directional relationship between periodontal disease and glycemic control has been 
demonstrated [9, 114]. 
 In the metabolic dysregulation of diabetes, persisting hyperglycemia causes non-
enzymatic glycation and oxidation of proteins and lipids, and the subsequent formation of AGEs, 
which accumulate in the plasma and tissues [115].  Hyperglycemia and resultant AGE formation 
are considered to be a major causal factor in the pathogenesis of diabetes complications [115].  
In addition, diabetes has been associated with altered collagen metabolism and increases the 
response of the periodontal tissue to pathogenic microorganisms, thereby increasing the 
severity of periodontal disease [116]. While the relationship between periodontal disease and 
glycemic control has been demonstrated in T1D, the association between oral immunological 
mediators and glycemic control in T1D is not well understood [117]. 
 
 21 
Matrix Metalloproteinases and Periodontitis 
A complex network of cytokines is involved in the inflammatory and immune responses 
in the inflamed periodontal tissues during the pathogenesis of periodontitis [118].  Among these 
cytokines, matrix metalloproteinases (MMPs)—a family of zinc endopeptidases (break peptide 
bonds of nonterminal amino acids) that degrade the extracellular matrix (ECM) and regulate 
fibrosis formation—has been thought to play a central role in the regulation of periodontal tissue 
turnover in health and disease [118].   MMPs are proteolytic enzymes that regulate changes in 
the extracellular matrix (ECM) and maintain its normal physiology and pathology [119].  MMPs 
are divided into six major groups depending on their substrate specificity of extracellular matrix 
proteins: collagenase, stromelysin, gelatinase, elastase, matrilysin, and membrane-bound 
MMPs [120]. 
The expression and activity of MMPs in adult tissues is normally quite low, but increases 
significantly in various pathological conditions, including inflammatory diseases, that may lead 
into unwanted tissue destruction.  MMP activity is increased due to an increased concentration 
of collagenase in periodontal pockets [121].  Several studies have shown that MMPs are useful 
as markers for people at risk for T1D [122, 123].  MMPs are produced by various cells (i.e. 
macrophages, lymphocytes and fibroblasts) and actively contribute to the destruction of 
periodontal tissues and eventual alveolar bone loss [124].   
 
Specific MMP Involvement and Periodontitis 
MMP-3 and Periodontitis 
MMP-3, also known as stromelysin-1, breaks down collagen and degrades 
proteoglycans and fibronectin.  MMP-3 levels have been shown to be elevated in GCF and from 
patients with periodontitis and in vitro in gingival fibroblasts [120].  Interestingly, extracellular 
levels were significantly elevated compared to intracellular levels.  Furthermore, increased 
MMP-3 mRNA expression has also been demonstrated in gingival samples from periodontitis-
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affected tissue.  This production is shown to be enhanced by the cytokines IL-1β and TNFα 
[120].  Human primary umbilical vein endothelial cells and monocyte-derived macrophages 
under high glucose conditions showed an increase in MMP-1 expression, while reducing MMP3 
expression, suggesting a dysregulation of MMPs under hyperglycemic conditions [125]. 
 
MMP-8 and Periodontitis 
MMP-8, also known as collagenase-2, has many roles, including breaking down 
collagenases, assisting with neutrophil migration, and inducing the expression of certain 
cytokines, such as IL-6 and IL-8 during inflammation [126, 127].  Several studies have shown 
that MMP-8 levels in the GCF and saliva are significantly elevated in periodontitis patients 
compared to healthy individuals [128, 129].  In one study investigating the various forms of 
MMP-8, it was discovered that less glycosylated forms are found to be derived from pro-
inflammatory mediators, such as IL-1β and TNF-α [130].  MMP-8 originates from mature 
neutrophils and degranulated neutrophils that have been attacked by bacteria.  Plasma cells 
located within inflamed periodontal tissue express MMP-8, however their molecular form is still 
under investigation. 
 
MMP-9 and Periodontitis 
MMP-9, also known as gelatinase B, is involved  tissue remodeling, wound healing, 
mobilization of matrix-bound growth factors and processing of cytokines [119].  MMP-9 is mainly 
secreted by polymorphonuclear leukocytes and degrades collagen (mainly type IV) present in 
gingival tissues and participates in basement membrane remodeling [131].  MMP-2 and MMP-9 
serum levels are thought to be abnormal in obese patients and significantly higher in T1D 
patients in comparison to control groups [123].  In a particular study investigating MMP-9 levels 
in subjects with chronic periodontitis with and without diabetes, MMP-9 levels were increased 
three-fold in subjects with chronic periodontitis with diabetes compared to without [116].  In 
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chronic periodontitis, levels of TIMP (tissue inhibitors of metalloproteinases) are low and thus 
inadequate to inhibit elevated MMPs.  Moreover, mobilization and activation of inflammatory 
cells, such as lymphocytes and neutrophils, alteration of immunomodulators and secretion of 
inflammatory proteases occur [131].   
 
PCA Analysis 
Principal components analysis (PCA) is a variable reduction technique used to account 
for redundancy between variables by producing uncorrelated components.  These components 
account for a meaningful amount of the variance contained in the original set of variables but 
that can be used simultaneously in a regression analysis.  The relationships between PCA 
components and HbA1c and gum health can be examined through multiple linear and logistic 
regression analyses. 
 
Hypothesis and Aims 
 The goal of this work is to characterize and measure oral inflammation in association 
with glycemic control, periodontal status, and glucose stimulation.  There have been no previous 
studies describing the distribution of salivary biomarkers of inflammation in T1D.  Thus, our 
overall hypothesis is that salivary biomarkers of inflammation will be associated with 
glycemic control and periodontal status in type 1 diabetes.  We will address the hypothesis 
via the following specific aims: 
 
Specific Aim 1 (presented in Chapter 3): Determine the association of salivary 
inflammatory burden, oral health, and glycemic control in T1D subjects. 
1.1 Recruit and collect saliva and metabolic parameters from 150 T1D patients. 
1.2 Measure the salivary levels of TNF-α, IL-1β, IFN-γ, IL-6, IL-8, and IL-10 as a 
determination of inflammatory burden. 
 24 
1.3 Determine the salivary levels of MMP-3, MMP-8, and MMP-9 as a measure of 
periodontal status. 
1.4 Utilize linear and logistic regression model analysis to evaluate the association of 
measured salivary inflammatory and periodontal markers with glycemic control and self-reported 
gum health.   
 
Specific Aim 2 (presented in Chapter 4): Measure the salivary diurnal inflammatory 
rhythms within the saliva of healthy adult subjects. 
2.1 Recruit and collect longitudinal intra-daily saliva samples from healthy adult subjects. 
2.2 Measure the cytokine levels within salivary samples by multiplexing analysis. 
2.3 Perform statistical analysis to determine if oral inflammatory diurnal rhythms are 
present and can be detected within the saliva. 
 
Specific Aim 3 (presented in Chapter 5): Evaluate impact of hyperglycemia on the 
inflammatory profile from a HSG cell line. 
3.1 Determine cytokine profile and measure cytokine production of the HSG cell line at 
basal and glucose stimulatory conditions. 
3.2 Elucidate the cellular signaling mechanism of enhanced inflammatory production 
during glucose-stimulatory conditions. 
 
Overall Impact and Significance 
 At the end of this work, our findings will allow us to better comprehend the impact of 
hyperglycemia on the inflammatory profile from salivary resources.  Additionally, we will better 
comprehend the cytokine diurnal rhythms in the saliva.  The objective of this research is to 
analyze the presence and distribution of salivary biomarkers of inflammation in T1D and 
periodontitis and investigate how these markers relate to glycemic control and self-reported gum 
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health.  The long term goal of this proposed project is to investigate the causal mechanisms 
associating inflammation, periodontal disease, and diabetes using oral biomarkers.  In addition, 
the results of this research could provide a new avenue into the investigation of using saliva 
instead of serum as a diagnostic fluid for evaluation of T1D management.   
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Figure 1: Timeline of Type 1 Diabetes 
This graph depicts the overall timeline of events that occur in individuals whom develop T1D.  1) 
A precipitating event or genetic predisposition occurs early in life.  2) The immune system 
develops and turnover of islet cells begin.  3) β cells start to destruct and autoantibodies form.  
4) Progressive loss of insulin release occurs and C-peptide levels decrease.  Some individuals 
may experience β cell relapse creating wavering levels.  5) Hyperglycemia, insulin resistance, 
and complete β cell loss results in overt diabetes (figure adapted from Atkinson et. al, 2014). 
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Figure 2: Immunological Mechanisms in Type 1 Diabetes 
(1) An APC (antigen presenting cell) binds to T cell receptors to stimulate T cells and B cells to 
become either cytotoxic or helper CD4+ cells.  (2.A) CD4+ cells will clonally expand and release 
cytokines, such as TNF and IL-1β, which recruit cytotoxic CD8+ T cells that release perforins 
and granzymes to damage pancreatic cell membranes or (2.B) B cells become activated and 
release autoantibodies that attack the pancreatic β cells.  (3) Insulitis of the pancreas occurs.  
MHC: major histocompatibility complex (Adapted from Waldron-Lynch, et. al, 2011). 
 
  
 28 
 
 
 
 
 
 
 
Figure 3: Overview of β Cell Apoptosis from an Inflammatory Standpoint 
Cytokines bind to their respective receptors located on the β cell and each cytokine plays a 
unique role in triggering apoptosis.  IFN-γ activates STAT1 via a Janus kinase (JAK)-signal 
transducer.  TNF can utilize either the FAS associated death domain (FADD) protein or the 
mitogen activated protein kinase (MAPK) pathway, which activate caspases.  Lastly, IL-1β 
activates the MAPK or nuclear factor-κB (NF-κB) pathways, which then activates inducible nitric 
oxide synthase (iNOS) to increase the production of nitric oxide (NO) to initiate β cell death 
(Adapted from Vetere et. al, 2014). 
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Figure 4: Hyperglycemic Events Leading to Inflammation 
During hyperglycemia, sugars undergo non-enzymatic glycation, creating Schiff bases and 
Amadori products.  These irreversible products are converted into advanced glycation end 
products (AGEs), which interact with receptors on monocytes and trigger inflammation via 
stress pathways, such as the NFκB pathway (Figure adapted from Dr. Alman). 
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Figure 5: Summary of the 3 Main Salivary Glands 
The parotid gland, located above the jaw and in front of the ear, secretes serous (water, 
electrolytes, enzymes) fluid through the parotid duct into the rear of the mouth.  The 
submandibular and sublingual glands secrete mucin-containing fluids and are located at the 
back of the mouth and under the floor of the tongue, respectively.  The submandibular gland 
secretes 65-75% of total salivary content, the sublingual gland secretes 5% of the total salivary 
content, and the parotid gland secretes 20% of the total salivary content (Image adapted by 
Pfaffe et. al, 2011). 
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Figure 6: Overview of the Biomolecular Flow from Capillaries to Salivary Acinar Cells 
From the capillaries, steroid hormones diffuse or actively transport into the saliva, whereas 
smaller molecules enter through the gap junctions.  Large proteins can be transported through 
gingival fluid and gum tissue (Figure adapted from Punyadeera et. al, 2013). 
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Chapter 2: Materials & Methods 
 
 
Saliva Collection and Enrollment of T1D Subjects 
All human saliva collections were approved by the University of South Florida 
Institutional Review Board.  152 T1D patients of the Carol and Frank Morsani Diabetes Center 
at the University of South Florida, aged 18 or older, were enrolled.  The study was explained to 
the subject and upon agreement, he/she was asked to passively drool in a 2 mL collection tube 
with a salivary collection aid attached to it.  At least 0.3 mL of saliva was collected for triplicate 
analysis.  Immediately upon receiving the saliva sample, a Thermo Scientific HaltTM protease 
and phosphatase inhibitor cocktail (EDTA-free) was added at 1x to prevent breakdown of 
proteins.  The sample was centrifuged for 5 minutes at 5500 rpm in a refrigerated centrifuge set 
at -10°C.  The saliva sample were distributed into 100 µL aliquots and stored at -80°C until 
assay.  The metabolic parameters, such as BMI and HbA1c, in addition to duration of diabetes, 
race, sex, time of collection, and age were collected from each subject.  Each subject was 
asked to answer two questions based on their oral health: 1) “Compared to others your age, 
how would you rate the present condition of your gums?” and 2) “Do you have a loose tooth?”  
The main steps of the enrollment process are summarized in Figure 7.  
 
Quality Control Saliva Preparation 
Commercially received pooled healthy human QC saliva (Innovative Research, Lot # 
11656) was prepared in 100 µL aliquots with and without protease and phosphatase inhibitor.  
Thermo Scientific HaltTM protease and phosphatase inhibitor cocktail (EDTA-free) were added 
at 1x immediately when received.  All samples were prepared in 100 µL aliquots and stored at -
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80°C.  QC saliva was diluted 1:2 in assay buffer prior to being tested to eliminate clogging of the 
probe in the Luminex Magpix® instrument.  
 
Luminex Magpix® Assays 
Measurement of Cytokine Levels 
Cytokine levels were determined using a high sensitivity human cytokine multiplexed 
bead immunoassay (Millipore, Catalog number HSCYTMAG-60SK).  T1D subject saliva, HSG 
lysate and media, and BNL lysate samples were performed in triplicate on each plate.  Diurnal 
saliva samples were performed in duplicate for each plate.  Prior to assay, further processing of 
the saliva samples included diluting them in a 1:2 ratio by adding 155 μL of saliva sample and 
155 μL of Assay Buffer.  Two quality control commercially received saliva samples (Innovative 
Research, Novi, MI) were also included in each run and they were diluted in a 1:2 ratio by 
adding 55 μL of sample and 55μL of Assay Buffer.  Nine cytokines- IL-1β, IL-2, IL-4, IL-6, IL-8, 
IL-10, IL-13, TNF-α, and IFN-γ- were measured using the high sensitivity human cytokine 
magnetic bead assay.  The high sensitivity human cytokine magnetic bead kit provides a 
minimum detectable concentration of IL-1β (0.06 pg/mL), IL-2 (28.48 pg/mL), IL-4 (16.87 
pg/mL), IL-6 (0.20 pg/mL), IL-8 (0.05 pg/mL), IL-10 (0.48 pg/mL), IL-13 (383.95 pg/mL), TNF- 
(0.07 pg/mL), and IFN- (0.18 pg/mL).  For every plate analyzed, concentrations were calculated 
by the StatLIA® Immunoassay Analysis software (Brendan Technologies), by measuring the true 
limits of detection for an assay by mathematically determining what the empirical Minimum 
Detectable Concentration (MinDC) would be if an infinite number of standard concentrations 
were run for the assay under the same conditions. 
To start, 200 μL of Wash Buffer was added to each well and mixed on the plate shaker 
at 400 rpm for 10 minutes at room temperature.  The Wash Buffer was decanted and residual 
amount was removed by inverting the plate and tapping it smartly onto absorbent towels several 
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times.  25 μL of microsphere beads coated with monoclonal antibodies against the six different 
target analytes were added to the wells.  Next, the plate was rested on a hand-held magnetic 
plate to allow complete settling of magnetic beads.  The well contents were removed by gently 
decanting the plate and tapping on an absorbent towel to remove residual fluid.  The plate was 
washed with 200 μL of 1x Wash Buffer.  The magnetic plate resting/wash process was repeated 
for a total of 2 times.  The plate was then prepared by adding 50 μL of each standard or control 
into appropriate wells.  The 0 pg/mL standard (background wells) consisted of 50 μL of Assay 
Buffer.  50 μL of the diluted saliva samples was added in triplicate to the plate, resulting in a 
total of 24 samples to be analyzed per plate.   
The plate was sealed, wrapped in foil, and incubated with agitation of 200-400 rpm on a 
plate shaker overnight at 4°C.  The plate was warmed to room temperature, the contents 
removed, and washed twice.  The detection bodies were warmed up to room temperature and 
50 μL was distributed to each well.  The plate was sealed, protected from light, and incubated 
with agitation of 200-400 rpm on a plate shaker for 1 hour at room temperature.  Then, 50 μL of 
Streptavidin conjugated to the fluorescent protein, R-Phycoerythrin, was added to each well and 
incubated at room temperature, protected from light, on a plate shaker set to 200-400 rpm for 30 
minutes.  The well contents were removed and the plate washed twice.  Lastly, 150 µL of Wash 
Buffer was added to all wells and the beads were resuspended on a plate shaker set at 200-
400rpm for 5 minutes.  The plate was analyzed on the Luminex Magpix® using a 5-parameter 
logistic curve-fitting method for calculating cytokine concentrations in the saliva samples.  This 
entire process is demonstrated in a brief summary in Figure 8. 
 
Measurement of Salivary MMP Levels 
MMP-3, MMP-8, and MMP-9 levels were determined using a multiplexed bead 
immunoassay (R&D systems Inc, Catalog number LMPM000, Minneapolis, MN).  The high 
sensitivity human cytokine magnetic bead kits provide a minimum detectable concentration of 
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MMP-3 (35.3 pg/mL), (MMP-8 (195.47 pg/mL), MMP-9 (157.94 pg/mL).  For every plate 
analyzed, concentrations were calculated by the StatLIA® Immunoassay Analysis software 
(Brendan Technologies), by measuring the true limits of detection for an assay by 
mathematically determining what the empirical Minimum Detectable Concentration (MinDC) 
would be if an infinite number of standard concentrations were run for the assay under the same 
conditions.  Prior to assay, further processing of the saliva samples included diluting them in a 
1:40 ratio by adding 10 μL of saliva sample and 390 μL of Calibrator Diluent. 
Two quality control saliva samples were also included in each run and they were diluted 
in a 1:40 ratio by adding 10 μL of sample and 390 μL of Calibrator Diluent.  MMP-3, MMP-8, 
and MMP-9 were measured using the high sensitivity human cytokine magnetic bead assay.  50 
μL of the microparticle cocktail, containing magnetic beads and MMP antibodies against the 
three target analytes, were added to every well of the microplate.  The plate was then prepared 
by adding 50 μL of each standard or control into appropriate wells.  The 0 pg/mL standard 
(background wells) consisted of 50 μL of Calibrator diluent.  50 μL of the diluted saliva samples 
were added in triplicate to the plate, resulting in a total of 24 samples to be analyzed per plate. 
The plate was sealed, wrapped in foil, and incubated with agitation of 200-400 rpm on a 
plate shaker for 2 hours at room temperature. Next, the plate was rested on a hand-held 
magnetic plate to allow complete settling of magnetic beads.  The well contents were removed 
by gently decanting the plate and tapping on an absorbent towel to remove residual fluid.  The 
plate was then washed with 100 μL of 1x Wash Buffer.  The magnetic plate resting/wash 
process was repeated for a total of 3 times.  50 μL of the Biotin Antibody cocktail was distributed 
to each well.  The plate was sealed, protected from light, and incubated with agitation of 200-
400 rpm on a plate shaker for 1 hour at room temperature.  Next, 50 μL of Streptavidin 
conjugated to the fluorescent protein, R-Phycoerythrin, was added to each well and incubated at 
room temperature, protected from light, on a plate shaker set to 200-400 rpm for 30 minutes.  
The well contents were removed and the plate washed three times.  Lastly, 100 µL of Wash 
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Buffer was added to all wells and the beads were resuspended on a plate shaker set at 200-400 
rpm for 5 minutes.  The plate was analyzed on the Luminex Magpix® using a 5-parameter 
logistic curve-fitting method for calculating cytokine concentrations in the saliva samples. 
 
Cytokine Array  
We screened for 40 chemokines/cytokines for expression in 5.5 mM, 11 mM, and 22 
mM-treated mouse liver BNL CL.2 (American Type Culture Collection, BNL CL.2, TIB-73) cells 
using a Mouse Cytokine Array Panel A (R&D Systems Inc, Catalog number ARY006, 
Minneapolis, MN).  Cell lysate was collected from mouse liver BNL cells and used for this 
protocol.  A nitrocellulose membrane coated with 40 different capture antibodies was added to a 
well of the 4-well multi-dish containing 2 mL of Array Buffer 6 and put on a rocking platform 
shaker for one hour.  As recommended by R&D Systems Inc., 500 µL of cell lysate was used 
and added to 0.5 mL of Array Buffer 4 and 1 mL of Array Buffer 6 was added to bring the final 
volume up to 1.5 mL.  Next, 15 µL of reconstituted Mouse Cytokine Array Panel A Detection 
Antibody Cocktail was added to each prepared sample, mixed, and incubated for 1.5 hours at 
room temperature.  The well was aspirated and the sample/antibody mixtures were added.  The 
well was incubated overnight at 2-8°C on a rocking platform shaker.   
The membrane was then removed and placed into a plastic container with 20 mL of 1x 
wash buffer for 10 minutes on a rocking platform shaker.  Two more washes were performed to 
make it a total of three washes.  Streptavidin-HRP was diluted 1:2000 in Array Buffer 6, as 
recommended on the vial label, and added to the membrane for incubation of 30 minutes on a 
rocking platform shaker.  Three washes were performed with 1x wash buffer and the membrane 
was placed on a plastic sheet protector and coated with 1 mL of Chemi Reagent Mix and 
incubated for one minute.  The membrane was exposed for 10 minutes using standard 
chemiluminescence on a Fuji Image Reader LAS 3000. 
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Cotinine Measurement 
 A high sensitivity cotinine ELISA (Salimetrics, Catalog number 1-2002, State College, 
PA) was used to determine cotinine levels in all T1D and healthy saliva samples collected.  
Saliva samples were thawed on ice and centrifuged at 1500 g for 15 minutes to remove mucins 
and other particulate matter that may interfere with antibody binding.  20 µL of standards, 
controls, and unknowns were pipetted into appropriate wells and were assayed in duplicate.  
Next, 100 µL of conjugate solution was added to each well and then 100 µL of antiserum was 
added to each well.  Antiserum was not added to the nonspecific binding control wells.  The 
plate was covered and incubated on a shaker for 1.5 hours at 37°C with constant mixing at 500-
600 rpm.  The plate was washed four times with 300 µL of 1X wash buffer using the Multiwash 
III® microplate washer.  Next, 200 µL of TMB (tetramethylbenzidine) buffer was added to each 
well, mixed at 500 rpm for 5 minutes, and incubated in the dark for 25 minutes at room 
temperature.  50 µL of stop solution was added and the plate mixed on a plate shaker at 500 
rpm for 3 minutes.  The plate was read using the VersaMaxPlus microplate reader within 10 
minutes of adding stop solution at 450nm and correction at 630nm was calculated.  Data was 
analyzed using the SoftMax Pro software version 5.4.1. 
 
Cell Culture, Maintenance, and Propagation 
The human submandibular gland (HSG) cell line was established from an irradiated 
human salivary submandibular gland [132] and was generously provided by Dr. Bruce Baum 
NIH/NIDCR.  HSG cells were cultured using Dulbecco’s Modified Eagle’s medium and Ham’s F-
12 nutrient mixture (DMEM/F12) (catalog # 11330-032 GIBCO; Thermo Scientific, Rockford, IL) 
supplemented with 10% fetal bovine serum (FBS) (Hyclone; Thermo Scientific, Rockford, IL), 
100 U/ml penicillin, 100 μg/ml streptomycin, and 2 mM L-glutamine in a CO2 incubator 
maintained at 5% CO2 and 37°C.  BNL CL.2 cells (American Type Culture Collection, BNL CL.2, 
TIB-73) were cultured using Dulbecco’s Modified Eagle’s medium (DMEM) with 4.5 g/L glucose, 
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L-glutamine, and sodium pyruvate (catalog # 10-013-CV; Corning Cellgro, Manassas, VA) 
supplemented with 10% fetal bovine serum (FBS) (Hyclone; Thermo Scientific, Rockford, IL), 
100 U/ml penicillin, 100 μg/ml streptomycin, and 2 mM L-glutamine in a CO2 incubator 
maintained at 5% CO2 and 37°C.  When passaging the cells, the split ratio was performed at 
1:10 and cells were detached from the tissue culture flask with 0.25% trypsin/1.0 mM 
ethylenediaminetetraacetic acid (EDTA) (Sigma–Aldrich Co., LLC St. Louis, MO).  The 
DMEM/F12 and DMEM media were changed every two days, and cells were allowed to reach 
80% confluence before exposure to glucose.   
 
Glucose Treatment of Cell Lines 
 HSG and BNL cells were cultured as previously described and were seeded at 1 million 
cells per well in a 6-well culture dish.  Following 24 hour overnight adherence of cells to the 
plate, the media in the wells were replaced with 3 mL of glucose-free media containing 1% FBS 
and starved for 5 hours.  The glucose-free media containing 1% FBS was removed via pipetting.  
Cells were treated in duplicate with 1 mL of three different concentrations of glucose: 5.5mM, 
11mM, and 22mM.  These concentrations were determined from the calculations that reflect the 
high, middle, and low HbA1c recordings in the 152 T1D subject cohort previously mentioned.  
For example, the average HbA1c, 8.3%, is equivalent to 11mM using the formula for average 
blood glucose in mmol/L: 1.583 * HbA1c(%) – 2.52. 
The BNL cell 6-well culture dish was incubated in a CO2 incubator maintained at 5% CO2 
and 37°C for 24 hours to stimulate hyperglycemic conditions.  The HSG cell 6-well culture dish 
was incubated in a CO2 incubator maintained at 5% CO2 and 37°C for 24 hours, 48 hours, and 
for 72 hours to stimulate hyperglycemic conditions.  These differences in time to exposure were 
compared and analyzed.    One experiment of 24 hour glucose stimulation was performed using 
BNL cells of similar passage number.  Six repeat experiments of 24 hours, 48 hours, and 72 
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hours of glucose stimulation were preformed using HSG cells of similar passage numbers.  Cell 
media was collected and frozen at -80°C until assay.   
 
Cell Lysate and Media Collection  
HSG and BNL cells were washed with 1mL of sterile phosphate-buffered saline (PBS) 
and 300 µL of MPER (Mammalian Protein Extraction Reagent) was added to each well.  For 
repeat experiments, 200 µL and 100 µL of MPER was utilized to maximize protein 
concentration.  The solutions were collected and centrifuged at 10,000 rpm for 5 minutes.  
Supernatant was removed and stored in -80°C until assay.  The total protein concentration was 
determined to normalize the amount of cytokines that were being released.   
 
Bicinchoninic Protein Assay 
 The Mircoplate Procedure of the Bicinchoninic Assay (BCA) kit (Pierce, Thermo 
Scientific, Product number 23227, Rockford, IL) was performed to quantitate total protein 
content of all saliva collections, cell culture media, and cell lysate.  Fresh standards (0, 25, 125, 
250, 500, 750, 1000, 1500, and 2000 µg/mL) were prepared by diluting the contents of one 
Bovine Serum Albumin (BSA) Standard ampule (2 mg/mL albumin standard) into several tubes, 
using water or MPER as the diluent, for analysis of saliva or cell culture respectively.  Each time 
the assay was performed, fresh standards were prepared.  The determination of BCA Working 
Reagent volume was calculated utilizing the following formula: (# standards + # unknowns) x (# 
replicates) x (200 µL of Working Reagent) = total volume of Working Reagent required.  The 
Working Reagent was prepared by mixing 50 parts of BCA Reagent A with 1 part Reagent B 
(50:1, Reagent A:B).  For a full microplate of 96 wells, 19.6 mL of Reagent A was added to 0.4 
mL of Reagent B.   
 Once all reagents and standards were prepared, 25 µL of each standard and unknown 
sample (in duplicate or triplicate depending on available sample volume) were pipetted into a 
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microplate well.  Next, 200 µL of Working Reagent was added to each well and mixed on a plate 
shaker for 30 seconds, followed by an incubation at 37°C for 30 minutes.  After cooling to room 
temperature, the plate was read at an absorbance of 562nm on the VersaMaxPlus microplate 
reader and data was analyzed using the SoftMax Pro software version 5.4.1. 
 
Enzyme-Linked Immunosorbent Assay 
 To confirm trends discovered in the Luminex Magpix® kits, a multi-analyte ELISArray™ 
kit (Catalog Number MEH-004A, Qiagen, Valencia, CA) was utilized to qualitatively measure 
levels of six cytokines: IL-1β, IL-6, IL-8, IL-10, TNF-α, and IFN-γ.  The protocol was followed per 
manufacturer’s instructions.  Sample Dilution Buffer 2 was utilized and saliva samples were not 
diluted as recommended by Qiagen.  Data was analyzed using the SoftMax Pro software 
version 5.4.1. 
An IL-8 ELISA (Enzyme-Linked Immunosorbent Assay) (R&D Systems Inc., Catalog 
number HS800, Minneapolis, MN) was performed to determine IL-8 levels in the HSG cell lysate 
and media to confirm the levels detected using the multi-plex Luminex Magpix® kit as previously 
mentioned.  The protocol was followed as per manufacturer’s instructions.  The protocol calls for 
the subtraction of readings at 650 nm from readings at 450 nm.  Analysis was performed on the 
results from this subtraction and data was analyzed using the SoftMax Pro software version 
5.4.1. 
 An IL-13 ELISA (R&D Systems Inc., Catalog number D1300B, Minneapolis, MN) was 
performed to determine IL-8 levels in the HSG cell lysate and media to confirm IL-13 trends 
detected using the multi-plex Luminex Magpix® kit as previously mentioned.  Data was analyzed 
using the SoftMax Pro software version 5.4.1. 
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Western Blotting Analysis 
 Human submandibular gland cells were lysed as previously described.  Protein 
concentration was calculated using the BCA Protein Assay (Pierce, Fisher Scientific, Pittsburg, 
PA) as previously described.  Protein concentration was normalized to the lowest sample.  
Premixed 4x Lammeli Sample Buffer (Bio-Rad Laboratories Inc., Catalog number 161-0737, 
Hercules, California) was diluted to 1x in samples.  Samples were loaded in the appropriate 
volume (30 µL or 50 µL) to a sodium dodecyl sulphate-polyacrylamide gel electrophoresis 
(SDS-PAGE) (4-15%, 10%, or 20%) gel.  The gel was ran at 110 volts until adequate separation 
was achieved, typically 2 hours.  The gel was transferred to a polyvinylidine difluoride (PVDF) 
membrane using a gel transfer stack (Novex, Life Technologies, Reference number IB401001) 
on the iBLOT™ (Invitrogen, iBlot®) apparatus.   
 The membrane was then washed for 10 minutes in TBST (Tris-buffered saline 
containing 0.1% Tween-20, Thermo Scientific, Rockford, IL) buffer on a plate rocker.  The 
membrane was blocked for 1 hour in Startingblock™ T20 TBS Blocking Buffer (Thermo 
Scientific, Product number 37543).  After blocking, the membrane was rinsed in TBST and the 
primary antibody, prepared with Startingblock™ buffer, was applied and incubated overnight at 
4°C on a plate rocker.  The next day, the primary antibody solution was collected and five 10 
minute washes were performed.  After all washes, an HRP-conjugated Goat Anti-Rabbit (Bio-
Rad, Hercules, CA) secondary antibody was applied to the membrane and incubated at room 
temperature on a plate rocker for 1 hour.  After incubation, five 10 minute washes were 
performed.  Lastly, an enhanced chemiluminescence Western Blotting Substrate solution 
(Pierce, Thermo Scientific, Product number 32106) was applied to the membrane and exposed 
in a GE Amersham Imager 600 (GE Healthcare Life Sciences, Pittsburgh, PA) at the automated 
recommended time. 
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Statistical Analyses 
 Statistics were performed using the Tukey’s Multiple Comparison, Two-Way Analysis of 
Variance (ANOVA), and One-way ANOVA tests using GraphPad Prism Version 5.04.  
Representation of p values is as follows: p>0.05 (not significant), p<0.05 (*), p<0.01 (**), 
p<0.001 (***), p<0.0001 (****). 
 
PCA and Prediction Model Analysis 
PCA with orthogonal rotation was used to produce linear components of the cytokine 
and MMP variables with shared variance.  Components may be thought of as independent 
constructs represented by the markers that load highly on that component.  Factor loads to 
indicate correlations between individual markers were determined for each component.  
Prediction models, such as multiple linear (HbA1c) and logistic (gum health) regression 
analyses, were performed to examine the relationships between the PCA components and 
HbA1c and gum health.  This analysis was adjusted for age, duration of diabetes, BMI, sex, and 
race.  All data analyses were performed using SAS/STAT 9.3 software (SAS Institute Inc., Cary, 
NC).  
 43 
 
 
 
 
 
 
Figure 7: Overview of Enrollment and Collection Process 
The main steps of the enrollment process and salivary collection for 150 T1D subjects are 
summarized here.  
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Figure 8: Detection of Cytokines Using Luminex Magpix® High Sensitivity Assay.   
This scheme summarizes the important steps of detecting cytokines in salivary samples from 
T1D subjects (Picture of Luminex Magpix® instrument and computer adapted from 
www.millipore.com). 
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Chapter 3: Tumor Necrosis Factor-Alpha, Matrix-Metalloproteinases 8 and 9 
Levels in the Saliva Are Associated With Increased Hemoglobin A1c in Type 1 
Diabetes Subjects 
 
 
Note to Reader: 
 The majority of this chapter has been previously published in Plos One and have been 
reproduced with permission from Plos One Open Access.  Dr. Burkhardt, Dr. Amy Alman, and 
Melanie Kuehl assisted with data analysis.  Melanie Kuehl performed all data acquisition.  Dr. 
Burkhardt, Melanie Kuehl, Dr. Amy Alman, and Dr. Henry Rodriguez assisted with study design. 
 
Abstract 
Background: Type 1 diabetes (T1D) is an autoimmune disease resulting in the targeted 
destruction of pancreatic β-cells and permanent loss of insulin production. Proper glucose 
management results in better clinical outcomes for T1D and provides a strong rationale to 
identify non-invasive biomarkers indicative or predictive of glycemic control.  Therefore, we 
investigated the association of salivary inflammation with HbA1c in a T1D cohort.    
Methods: Unstimulated saliva was collected from 144 subjects with T1D at the USF 
Diabetes Center.  BMI, duration of diabetes, and HbA1c was recorded during clinical visit. 
Levels of interleukin (IL)-1β, -6, -8, -10, IFN-γ, TNF-α, MMP-3, -8, and -9 were measured using 
multiplexing immunoassay analysis.  To account for smoking status, salivary cotinine levels 
were also determined.   
Results: Multiple linear (HbA1c) and logistic (self-reported gingival condition) regression 
analyses were performed to examine the relationships between the Principal Component 
Analysis (PCA) components and HbA1c and gingival condition (adjusted for age, duration of 
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diabetes, BMI, and sex; model for HbA1c also adjusted for gingival condition and model for 
gingival condition also adjusted for HbA1c). PCA components 1 (MMP-8 and MMP-9) and 3 
(TNF-α) were significantly associated with HbA1c (β=0.28 ±0.14, p=0.045; β=0.31 ±0.14, 
p=0.029), while PCA component 2 (IL-6, IL-1β, and IL-8) was significantly associated with 
gingival condition (OR 1.60 95% CI 1.09-2.34, p=0.016).  In general, increased salivary 
inflammatory burden is associated with decreased glycemic control and self-reported gingival 
condition. 
Conclusions: The saliva may represent a useful reservoir of novel noninvasive 
inflammatory biomarkers predictive of the progression and control of T1D. 
 
Introduction 
Periodontitis impacts as much as 47% of the U.S. population and is a significant cause 
for tooth loss in adults [5].  This destructive process is driven by bacterial infections that colonize 
the tooth root surface [6].  Due to this pathogenic event, immunological mediators are activated 
and various metabolic byproducts such as cytokines, chemokines and tissue-destructive 
enzymes such as matrix-metalloproteinases (MMPs) are released [7].  Spillover of these 
immunological mediators into the general circulation is thought to play a role in the development 
and exacerbation of systemic diseases, particularly poorly controlled diabetes, whereby a bi-
directional relationship between periodontal disease and glycemic control has been suggested 
[9, 114].  Type 1 diabetes (T1D) is a highly complex polygenic autoimmune disease resulting in 
the loss of pancreatic β-cells and absence of insulin production [15].  While the relationship 
between periodontal disease and glycemic control has been demonstrated in T1D [117], the 
association between oral immunological mediators and glycemic control in T1D is not well 
understood and has not been precisely measured.  The overall suspected relationship between 
periodontal disease and glycemic control provides a strong rationale for our central hypothesis 
that increased inflammatory burden and quantitative biomarkers of periodontal disease will be 
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associated with decreased glycemic control.  To our knowledge, this has never been evaluated 
in a T1D cohort.   
Saliva is a clear mucoserous exocrine derived liquid containing a mixture of secretions 
from the submandibular, parotid, sublingual and minor glands that provides a representation of 
overall health status and oral inflammatory burden [11, 102, 111].  Saliva can be obtained 
noninvasively, safely and economically with minimal processing and required training by 
personnel.  Inflammatory molecules within the saliva are derived from the periodontium via 
influx of GCF and from the mucosa [133].  This bio-collection serves as a highly accessible and 
useful general measurement of oral inflammatory and periodontal burden.  Despite the 
tremendous potential and utility of the saliva for the examination of biomarkers related to 
systemic disease, limited studies have been conducted in understanding and evaluating the 
salivary inflammatory burden specifically in T1D [108-110].  At present, numerous potential 
surrogate measures of existing periodontal disease and oral health have been identified and 
include cytokines and MMPs such as interleukin-1β (IL-1β), tumor necrosis factor (TNF)-α, and 
matrix metalloproteinase (MMP)-8 [111, 134-136].  The utility of these biomarkers has been 
demonstrated in terms of association with decreased oral health but there are currently no 
published reports to our knowledge that have examined the association between oral 
inflammation and levels of HbA1c within T1D.   
To address this, we conducted an original study to examine the association between 
salivary inflammatory burden with glycemic control (HbA1c) and self-reported gingival condition 
in adult T1D subjects recruited from the University of South Florida Diabetes Center.   
 
Materials & Methods 
Participants 
A cross-sectional observation study of 152 T1D patients consecutively recruited from the 
Diabetes Center at the University of South Florida, aged 18 or older, was conducted to examine 
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the association between salivary inflammation and glycemic control.  Subjects were recruited 
during regularly scheduled clinic visits.  Of the 152 that were enrolled and that provided an 
unstimulated whole saliva sample (described below), 6 subjects were excluded from this 
analysis due to their saliva being very viscous and/or evidently contaminated with blood.  Nine 
additional subjects were excluded from the MMP analysis due to inadequate quantity of saliva.  
Only 2 subjects approached refused to participate in the study on the basis of overall 
apprehension of salivary collection.   
Since there are no published reports of the relationship between HbA1c and salivary 
cytokine levels in T1D, we have had to base sample size calculations on data from an 
independent cohort study of adult T1D that used serum measurements.  The independent 
cohort we used did not have measurements for all of the inflammatory cytokines that we are 
proposing to measure, and due to the possibility that individual inflammatory markers may act 
on several different pathways to arrive at the same outcome, we based the sample size 
calculation on a measure of inflammatory burden. We would have a power of >80% to detect a 
difference in sample means of 0.29 in the inflammatory burden variable using a dichotomization 
of subjects on HbA1C of ≥ mean vs. < mean.  The study was reviewed and approved by the 
University of South Florida Institutional Review Board.  All participants provided informed written 
consent prior to participation in the study.   
 
Clinical Data Collection 
All enrolled patients in the study completed the oral health questionnaire.  This 
questionnaire consisted of two questions regarding gingival condition: 1) Compared to others 
your age, how would you rate the current condition of your gums: poor, fair, good, excellent, and 
2) Do you have a loose tooth?  These questions were previously shown to be correlated with 
clinically determined periodontal health [137].  Additional information obtained from the patient 
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chart at the time of the clinic visit included body mass index (BMI), duration of diabetes, age, 
sex, race, and glycated hemoglobin (HbA1c), a measure of glycemic control. 
 
Saliva Collection 
Each participant passively drooled in a 2 mL collection tube with an attached salivary 
collection aid (Saliva Biol LLC No. 61/524096, patent pending).  Approximately 1 to 1.5 ml of 
saliva was collected from each subject.  Immediately upon collection a protease and 
phosphatase inhibitor cocktail (EDTA-free Thermo Scientific HaltTM, Thermos Fisher Scientific, 
Rockford, IL) was added at 1X to inhibit proteolysis.  The sample was centrifuged for 5 minutes 
at 5500 rpm in a refrigerated centrifuge set at -10°C.  The saliva sample was then distributed 
into 100 µL aliquots and stored immediately at -80°C until multiplexing analysis.  Commercially 
received saliva (Innovative Research, Novi, MI) was also aliquoted and stored frozen to be later 
used within each multiplexing batch for the purpose of quality control. 
   
Cytokine Analysis 
Cytokine levels were determined using a multiplexed bead immunoassay and measured 
with a Luminex Magpix® instrument (Luminex, Austin, TX). Six cytokines: IL-1β, IL-6, IL-8, IL-10, 
TNF-α, and IFN-γ were measured using the high sensitivity human cytokine magnetic bead 
assay (EMD Millipore, Cat No. HSCYTMAG-60SK-06, Billerica, MA) following manufacturer 
instructions as described in Chapter 2.  Quality control samples of non-T1D saliva were included 
in each assay run to account for any potential intra or inter-assay variability to ensure that % CV 
did not exceed 3%.  Measurements were performed in triplicate. 
 
MMP Analysis 
Human matrix metalloproteinase (MMP) levels were determined using a multiplexed 
bead immunoassay as described in Chapter 2.  Three MMPs: MMP-3, MMP-8, and MMP-9 
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were measured using the high sensitivity human MMP Base magnetic bead assay (R&D 
systems Inc, Catalog number LMPM000, Minneapolis, MN).  The plate was analyzed on the 
Luminex Magpix® instrument as described in Chapter 2 for determination of cytokine 
concentration.  Measurements were performed in triplicate.   
 
Cotinine Analysis 
Salivary cotinine levels were measured utilizing a commercial ELISA (Salimetrics, 
Catalog Number 1-2002, Carlsbad, CA) according to manufacturer’s instructions as described in 
Chapter 2.  Cotinine levels (ng/ml) were determined from 20 µl of saliva and measured in 
duplicate.  Due to saliva volume limitations of T1D subjects, cotinine levels were determined for 
95 of the 144 subjects.  Results are reported as means and standard deviations.   
  
Statistical Analysis 
Data are presented as means and standard deviations for continuous variables and as 
the number of subjects and percent for categorical data.  Distributions of all of the cytokines and 
MMPs were found to be skewed and were log transformed for all analyses. For these variables, 
the data are presented as the geometric mean and interquartile range.  All cytokines were 
adequately measured within the linear range of the generated standard curve with the exception 
of IFN- which was only measured in 2.1% of all salivary samples analyzed and therefore 
excluded from further analyses.  Cotinine-derived smoking status was determined using a cutoff 
value of 15 ng/ml [138, 139]. 
Principal components analysis (PCA) with orthogonal rotation was used to produce 
linear components of the cytokine and MMP variables with shared variance.  PCA is a variable 
reduction technique used to account for redundancy between variables by producing 
uncorrelated components that account for a meaningful amount of the variance contained in the 
original set of variables but that can be used simultaneously in a regression analysis.  
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Components may be thought of as independent constructs represented by the markers that load 
highly on that component.  Interpretability of the final solution was a major determinant of the 
minimum number of components to be used in the analyses.  Individual cytokines were 
considered to load highly on a given component with factor loads >0.6.  Factor loads indicate 
the correlation of individual markers on each component.  Multiple linear (HbA1c) and logistic 
(gingival condition) regression analyses were performed to examine the relationships between 
the PCA components and HbA1c and gingival condition.   
Both the linear (HbA1c) and logistic (gingival condition) models were adjusted for age, 
sex, duration of diabetes, and BMI.  The HbA1c model was additionally adjusted for gingival 
condition and the gingival condition model was additionally adjusted for HbA1c.  Cotinine-
derived smoking status, race, and time of saliva collection were evaluated as potential 
confounders and not found to alter the parameter estimates for the PCA components in either 
model by more than 10%, so these were not retained in the final models.  All data analyses 
were performed using SAS/STAT 9.3 software (SAS Institute Inc., Cary, NC). 
 
Results 
Study Design and Concentrations of Cytokines and MMPs in Saliva 
152 T1D subjects were enrolled in this study.  Subjects 066 and 074 were not tested or 
analyzed due to missing information.  Subject 031 was not analyzed for MMP levels due to lack 
of saliva sample quantity.  The overall characteristics of the subject population are shown in 
Table 1 and Figure 9.  The mean age of subjects in this study population was 35.8 (±16.5) 
years.  The study population had slightly more females than males (59% vs 41%) and was 
predominantly white (79.2%).  The mean duration of diabetes was 18.4 (±12.9) years, with a 
mean HbA1c of 8.3 (±1.7), and a mean BMI of 27.4 (±6.3).  Saliva was collected mostly in the 
afternoon (12:00 pm to 4:00 pm) and the majority of subjects (97%) reported no loose teeth.   
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The geometric means of the analytes ranged from 0.25 pg/ml for TNF-α to 305.0 ng/ml 
for MMP-9.  Figures 10 and 11 portray the mean levels of MMP and cytokine concentrations, 
respectively, of commercially received quality control saliva ran on all six Luminex Magpix® 
plates.  Figures 12 and 13 demonstrate the mean MMP and cytokine levels of the 144 T1D 
cohort, respectively.   
 
Cotinine Analysis 
Cotinine is a bi-product of nicotine and its levels can be detected up to 4 days for light 
smoking, 5 days for medium smokers, up to 10 days in heavy or addicted smokers, and for 
more than 10 days in people who chew tobacco [140].  Nicotine can only be detected up to 10 
hours in the saliva [140], therefore we measured cotinine levels.  Ninety-five subjects were 
analyzed for smoking status through detection of cotinine in the saliva.  Cotinine values 
indicated that 18 (19.0%) were current smokers or exposed to second-hand smoke.  Figure 14 
shows the ELISA results of cotinine levels in the T1D participants’ saliva.   
 
Total Salivary Protein Levels 
Total salivary protein was analyzed in each T1D subject (Figure #) following the protocol 
from the BCA protein kit as previously described in Chapter 2.  Due to limited sample volume, 
only 47 T1D subjects could be analyzed.  We did not observe any significant differences in 
protein content, as shown in Figure 15.  
 
Principal Components Analysis  
Table 2 presents the 5-component solution derived from the PCA.  MMP-8 and MMP-9 
were positively correlated with component 1 with factor loads of 0.89 and 0.88, respectively.  IL-
6, IL-1β, and IL-8 (factor loads of 0.82, 0.70, and 0.63, respectively) were highly correlated with 
component 2.  Components 3, 4, and 5 were correlated with single analytes, TNF-α (factor load 
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of 0.84), IL-10 (factor load of 0.87), and MMP-3 (factor load of 0.79), respectively.  Subjects with 
high values on any or all of these components would also have high values for the respective 
markers that loaded highly on the component.  
 
Multiple linear and logistic regression model of PCA components 
Table 3 presents the results of the multiple linear regression model of the PCA 
components on HbA1c, adjusted for age, sex, race, BMI, duration of diabetes, and gingival 
condition.  In this model, a significant linear association was found between PCA component 1 
(MMP-8 and MMP-9 loaded highly) and PCA component 3 (TNF-α loaded highly) with HbA1c (β 
0.28 ± 0.14, p=0.045; β 0.31 ± 0.14, p=0.029; respectively).  The other PCA components were 
not found to be linearly associated with HbA1c (p>0.05).  
 
Table 4 summarizes the results of the multiple logistic regression model of the PCA 
components on the self-reported gingival condition.  PCA component 2 (in which IL-6, IL-1β, 
and IL-8 loaded highly) was significantly associated with poorer gingival condition (OR 1.60, 
95% CI 1.09-2.34; p-value 0.016) after adjustment for age, duration of diabetes, HbA1c, BMI, 
and sex.  This result suggests that high values for these markers are associated with decreased 
gingival condition.  None of the other PCA components were significantly associated with 
gingival condition (p>0.05). 
 
Discussion 
This study demonstrated that specific salivary inflammatory markers in T1D subjects are 
associated with decreased glycemic control.  Two principal components were associated with 
decreased glycemic control.  The inflammatory markers that loaded strongly on these 
components were MMP-8, MMP-9, and TNF-α.  This is the first study that we are aware of to 
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examine the association of multiple salivary inflammatory biomarkers with glycemic control and 
self-reported gingival condition in T1D subjects. 
Prior studies examining salivary inflammatory levels within general systemic diseases, 
T1D, and T2D have demonstrated that specific mediators of inflammation are elevated within 
the saliva of these respective cohorts.  A large study examining the salivary concentrations of 
1000 adults in southern Sweden for levels of IL-1, -6, -8, TNF-, and MMP-8 (similar to 
inflammatory markers examined in this study) measured increased levels of: (1) IL-8 in subjects 
with tumor and bowel diseases, (2) MMP-8 in those following cardiac surgery or with diabetes 
and muscle diseases and (3) IL-1, -8, and MMP-8 in those having muscle or joint diseases 
[135].  With regard to salivary inflammatory burden in T1D, Dakovic et al. examined IL-8 salivary 
levels in T1D subjects with or without concomitant periodontitis versus the non-T1D cohort 
(n=20 per group) [141].  Measured levels of IL-8 were significantly elevated in T1D subjects as 
compared to the non-T1D group.  Within the T1D cohort, IL-8 levels were not associated with 
either periodontitis or clinical parameters.  In respect to T2D, Yoon et al. examined unstimulated 
saliva samples in 192 subjects with or without T2D and revealed that IL-1β concentration in 
saliva was mainly associated with the degree of periodontal disease not diabetes [111].   
Another investigation demonstrated that poor glycemic control (HbA1c > 8) was 
significantly associated with increased IL-1β levels in GCF in T2D [142].  In a later report, IL-8 
levels did not associate with increased HbA1c [143].  Taken together, these findings solidify the 
central hypothesis that salivary inflammatory burden can be associated with diseases of 
autoimmunity, metabolic control and periodontitis.  However, the specific relationship between 
certain cytokines such as IL-1β and either glycemic or periodontal status can be contradictory 
and requires further characterization.   
Proteomic and peptidomic analysis has revealed significant differences in the saliva 
between those subjects with T1D and periodontitis versus those with T1D and without 
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periodontitis [108-110].  Concordantly, a recent study evaluating 153 subjects with T1D or T2D 
examined the proteomic profile of these individuals stratified by their HbA1c levels ranging from 
<7 to >10 [144].  PCA and cluster analysis revealed that salivary proteomic changes were 
associated with HbA1c sub-groupings and to some extent supported our findings in that systemic 
glycemic levels are reflected within the salivary milieu in an HbA1c dependent manner.  Their 
findings revealed that salivary proteomes are distinctly segregated when compared with low 
(HbA1c <7), medium (8-9), and high (>10) HbA1c levels.  The proteomic changes based on HbA1c 
were stronger in T1D rather than T2D subjects and the identified salivary proteins associated 
with HbA1c changes in individual samples included albumin, hemoglobin, alpha-2-macroglobin, 
serum amyloid A, sereotransferrin, and numerous others.  Interestingly, neither cytokines nor 
MMP’s were identified within the salivary proteome as associated with HbA1c within T1D.  This 
may have been attributed to a sensitivity issue whereby these inflammatory mediators are 
potentially below the detection level for this proteomic approach.  There was no mention of 
periodontal status within this study.  Nonetheless, their findings in combination with our report 
clearly demonstrate that glycemic levels as reflected by HbA1c can be associated and 
represented in the saliva as measured by various biomarkers that can originate from the 
salivary gland, serum, or host immune system. 
A recent report by Engebretson et al. revealed that periodontal intervention (non-
surgical) failed to promote glycemic control in T2D subjects displaying moderate to advanced 
chronic periodontitis [145].  These findings would be somewhat discordant with our conclusions 
indicating that increased inflammatory burden is association with decreased glycemic control.  
However, systematic reviews and meta-analysis of numerous studies examining this 
relationship have indicated that periodontal treatment can result in modest reduction of HbA1c 
in combination with improvement of periodontal status in T2D subjects [146-149].  This type of 
comprehensive analysis has yet to be as extensively examined in T1D subjects with varied 
periodontal status as this was the primary cohort of our described study.  Nonetheless, our 
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results are certainly consistent with the overall theme that oral inflammatory levels are 
associated with glycemic control and potentially autoimmunity in T1D.    
A potential weakness of our study is the lack of a non-T1D control group.  The primary 
focus of this study was to measure and determine the association of salivary inflammation with 
glycemic control within T1D.  Since glycemic control is an important component of T1D clinical 
management, but not for those without diabetes, we felt that this population was particularly 
relevant for this initial study.  Previous literature has examined the gross comparison of salivary 
inflammation between diabetic (T1D and T2D) and non-diabetic controls and therefore, we did 
not intend to repeat these examinations [111, 141].  While we are not able to perform a 
comparison with non-diabetic controls, we are able to demonstrate that salivary inflammatory 
markers are significantly associated with increasing HbA1c in a linear model, after adjustment for 
potential confounders.   
Another potential limitation of this study is absence of a clinical dental exam with 
recorded measurement of pocket depth and bleeding on probing.  Unfortunately, we were 
unable to perform a clinical exam due to both economic and logistical reasons.  However, the 
primary objective of this study was to measure and examine quantitative measures of salivary 
inflammation with glycemic status in a T1D cohort.  Clinical measures of periodontitis and 
periodontal inflammation obtained from an examination is strictly a qualitative determination of 
the inflammatory response.  For our analysis, clinical measurements would certainly have 
provided some utility but would not have provided the quantitative assessment needed for our 
objectives.  Nonetheless, we still accounted for this via self-reported gingival condition.  
Measurement of inflammatory mediators in the saliva provides a more comprehensive analysis 
of oral inflammation [133].  In addition, the inflammatory mediators utilized within this study that 
had the greatest association with increased HbA1c levels (TNF-α, MMP8 and MMP9) have all 
been previously documented to be increased and associated with decreased periodontal status 
[136, 150, 151].  Therefore, it is reasonable to speculate that those individuals with elevated 
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inflammatory burden also potentially had decreased periodontal health.  Future studies are 
anticipated to include a comprehensive dental exam in combination with measurement of 
inflammatory burden and glycemic status.   
Salivary diagnostics has tremendous translational potential for numerous biological and 
technical reasons.  The outstanding utility of the saliva for serving as a clinical focal point during 
routine dental examinations or physician visits and potentially enabling large investigational 
studies certainly warrants this effort.  As compared to blood collection, salivary evaluation is 
relatively easy to obtain with high patient compliance (in our study only 1% of subjects declined 
participation) and can be performed by minimally trained personnel with little post-collection 
processing.  Our study has suggested that the salivary inflammatory burden may also be an 
indication of glycemic status or clinical management in T1D.  These data can be further utilized 
to establish novel clinical diagnostic tools to promote patient compliance and enhance 
subsequent clinical application of interventional therapy.  In addition, oral inflammatory burden 
with biomarkers described in this publication may also be combined with other biomarkers (i.e. 
autoantibodies in the case of T1D) either circulating or from the saliva that can be implemented 
to generate predictive models to identify subjects in the early stages of either developing 
autoimmunity or glucose intolerance. 
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Table 1: T1D Subject Characteristics (n=144) 
 
Characteristics  
Age (years)* 35.8 ±16.5 
Male (n)† 59 (41.0) 
Race/ethnicity (n) †  
White 114 (79.2) 
Black 13 (9.0) 
Hispanic 12 (8.3) 
Other 5 (3.5) 
Duration of diabetes (years)* 18.4 ±12.9 
HbA1c (%)* 8.3 ±1.7 
BMI (kg/m2)* 27.4 ±6.3 
BMI category (n)†  
Underweight (<18.5  kg/m2) 5 (3.5) 
Normal (18.5-<25 kg/m2) 52 (36.1) 
Overweight (25-<30  kg/m2) 51 (35.4) 
Obese (≥30 kg/m2) 36 (25.0) 
Cotinine (ng/ml)‡,§ 1.1 (0.3–1.7) 
Current smoker (n; cotinine > 25 ng/ml)†,§ 18 (19.0) 
Time of day of saliva collection (n)*  
Morning (8:50 am to 11:58 am) 54 (37.5) 
Afternoon (12:00 pm to 5:07 pm) 90 (62.5) 
Condition of gums (n)†  
Excellent 20 (13.9) 
Very Good 43 (30.0) 
Good 53 (36.8) 
Fair 25 (17.4) 
Poor 3 (2.1) 
Has a loose tooth (n)† 5 (3.5) 
IL-6 (pg/ml)‡ 1.8 (0.61-6.8) 
IL-8 (pg/ml)‡ 54.6 (22.2-118.3) 
IL-10 (pg/ml)‡ 6.9 (2.6-18.6) 
IL-1β (pg/ml)‡ 1.1 (0.27-4.7) 
TNF-α (pg/ml)‡ 0.25 (0.13-0.50) 
MMP-3 (pg/ml)‡,‖ 197.5 (77.3-377.0) 
MMP-8 (ng/ml)‡,‖ 84.1 (35.5-183.6) 
MMP-9 (ng/ml)‡,‖ 305.0 (140.4-680.7) 
*Data presented as mean ±SD, †Data presented as number (%), ‡Data presented as geometric 
mean (25th-75th percentile), §N=95, ‖N=135  
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Figure 9: Statistical Collection Data of 144 T1D Subjects 
(A) Patient saliva collection times.  Morning is defined as 12:00am to 11:59am, afternoon is 
defined as 12:00pm to 4:00pm, and evening is defined as 4:59pm to 12:00am.  (B) Percentage 
of answers to “Do you have a loose tooth?”  (C) Percentages of answers to “Compared to 
others your age, how would you rate the present conditions of your gums?” 
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Figure 10: Mean MMP Levels of QC Saliva Samples 
Commercially received Quality Control saliva was included on each Luminex Magpix® plate with 
the T1D saliva samples.  Mean MMP levels were measured in these quality control samples 
with and without inhibitor to determine to demonstrate minimal inter-assay variability. 
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Figure 11: Mean Cytokine Levels of QC Saliva Samples 
Commercially received Quality Control saliva was included on each Luminex Magpix® plate with 
the T1D saliva samples.  Mean cytokine levels were measured in these quality control samples 
with and without inhibitor to determine to demonstrate minimal inter-assay variability.  The red 
dotted line indicates the minimum detection concentration of the assay, which was 0.13 pg/mL. 
Error bars represent SEM.  
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Figure 12: Mean MMP Levels of 144 T1D Subjects 
Total combined salivary MMP levels of 144 T1D subjects across all 6 Luminex Magpix® plate 
runs.  All results fell within the standard curve from mid- to low-range.  Minimum detection levels 
were the following: MMP-3: 35.3 pg/mL, MMP-8: 81.9 pg/mL, and MMP-9: 100.3 pg/mL.  Error 
bars represent SEM. 
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Figure 13: Mean Cytokine Levels of 144 T1D Subjects 
Total combined salivary cytokine levels of 144 T1D subjects across all Luminex Magpix® plate 
runs.  A) Shows the total mean in bar chart form.  B) Demonstrates a scatter plot of all 144 T1D 
subjects.  All results fell within the standard curve from mid- to low-range.  The red dotted line 
indicates the minimum detection concentration of the assay, which was 0.13 pg/mL.  Error bars 
represent SEM.  
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Figure 14: Cotinine Levels of 95 T1D Subjects 
Unstimulated whole saliva was collected from 95 T1D subjects and their saliva was analyzed on 
3 ELISA cotinine plates.  (A) Mean result of 37 subjects (performed in duplicate) from the 
subject range 001 – 053, (B) Mean result of 39 subjects (performed in duplicate) from the 
subject range 054-130, (C) Mean result of 19 subjects (performed in duplicate) from the subject 
range 131-152.  The standard curve is represented by red diamonds and the blue dots indicate 
each individual saliva sample.  The standard curve ranged from 0.8 ng/mL to 200 ng/mL.  Any 
result greater than 25 ng/mL indicates a smoker or an involvement of second-hand smoke. 
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Figure 14 continued 
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Figure 15: Salivary Protein Levels of 47 T1D Patients 
Remaining saliva from 47 T1D subjects was tested using a BCA protein kit (Thermo Scientific, 
product number 23227, Rockford, IL).  Due to limited sample, not all saliva could be analyzed.  
Standard curve ranged from 0 µg/mL to 2000 µg/mL.  Bars represent the median result of the 
duplicate samples. 
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Table 2: Principal Components Analysis with Orthogonal Rotation of the Individual 
Cytokines and MMPs 
 
Component 1 Component 2 Component 3 Component 4 Component 5 
Marker Load* Marker Load* Marker Load* Marker Load* Marker Load* 
MMP-8 0.89† IL-6 0.82† TNF-α 0.84† IL-10 0.87† MMP-3 0.79† 
MMP-9 0.88† IL-1β 0.70† IL-1β 0.40 IL-6 0.27 IL-6 0.34 
IL-8 0.49 IL-8 0.63† IL-8 0.35 TNF-α 0.26 MMP-9 0.24 
IL-1β 0.44 TNF-α 0.35 IL-10 0.24 IL-8 0.26 MMP-8 0.19 
MMP-3 0.39 MMP-3 0.33 MMP-3 0.21 MMP-3 0.22 IL-10 0.19 
IL-10 0.25 IL-10 0.28 IL-6 0.19 MMP-9 0.20 TNF-α 0.19 
TNF-α 0.23 MMP-8 0.26 MMP-8 0.19 MMP-8 0.17 IL-8 0.15 
IL-6 0.16 MMP-9 0.22 MMP-9 0.15 IL-1β 0.15 IL-1β 0.11 
*Factor loads are determined by the Pearson correlation coefficient of the marker on the 
component, †Factor loads >0.6 were considered for the interpretation of the component 
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Table 3: Multiple* Linear Regression of PCA Components on HbA1c  
 
Marker β ±SE p-value 
PCA Component 1 (MMP-8 & MMP-9) 0.28 ±0.14 0.045 
PCA Component 2 (IL-6, IL-1β, & IL-8) -0.02 ±0.14 0.901 
PCA Component 3 (TNF-α) 0.31 ±0.14 0.029 
PCA Component 4 (IL-10) -0.11 ±0.14 0.421 
PCA Component 5 (MMP-3) 0.21 ±0.14 0.123 
*Adjusted for age, duration, BMI, sex, and gingival condition 
 
 
Table 4: Multiple* Logistic Regression of PCA Components on Condition of Gums (Poor 
+ Fair + Good vs. Very Good + Excellent) 
 
Marker OR (95% CI) p-value 
PCA Component 1 (MMP-8 & MMP-9) 1.16 (0.79, 1.70) 0.463 
PCA Component 2 (IL-6, IL-1β, & IL-8) 1.60 (1.09, 2.34) 0.016 
PCA Component 3 (TNF-α) 0.75 (0.52, 1.10) 0.141 
PCA Component 4 (IL-10) 1.07 (0.74, 1.54) 0.717 
PCA Component 5 (MMP-3) 1.05 (0.72, 1.53) 0.798 
*Adjusted for age, duration of diabetes, HbA1c, BMI, sex 
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Chapter 4: Measurement of Diurnal Pattern of Oral Inflammation in Healthy Adults 
 
 
Abstract 
There has been an increased interest in utilizing the saliva as a diagnostic fluid, 
particularly with regard to assessing markers of inflammation for indicators of systemic 
diseases, periodontitis, or stress.  However, future clinical utility of the saliva cannot be fully 
assessed without a detailed examination of standard circadian rhythm for these potential 
markers.  In addition, numerous inflammatory diseases such as rheumatoid arthritis (RA) have 
revealed that onset of symptoms can correlate with diurnal fluctuations.  This suggests that 
circadian rhythm may also regulate disease pathology.  To examine the daily fluctuation of 
inflammation to provide necessary understanding into these potential diagnostic parameters, we 
measured levels of IL-1β, IFN-γ, IL-6, IL-8, IL-10, and TNF-α simultaneously in the saliva of 12 
healthy young adults.  Saliva samples were collected 6 times a day according to individual’s 
sleep schedule (wake, wake + 30 minutes, wake + 3 hours, wake + 6 hours, wake + 9 hours, 
and immediately preceding sleep).  This study demonstrated that salivary inflammatory markers 
have unique diurnal patterns and may affect the overall inflammatory response.  Additionally, 
diurnal patterns of IFN-γ and TNF-α remained elevated in the morning over three consecutive 
days.  In summary, we have revealed that specific cytokines are regulated by circadian rhythm 
and indicate that utilizing these as biomarkers for systemic disease must be noted and observed 
in accordance with time of measurement with regard to sleep schedule. 
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Introduction 
Saliva is a clear mucoserous exocrine derived liquid containing a mixture of secretions from 
the [102] three major glands involved in secretion: parotid, submandibular, and sublingual.  The 
parotid gland is the largest and secretes serous saliva, while the others secrete saliva 
containing mucous [104].  Saliva has a multitude of biological functions including: lubrication, 
enamel maintenance, buffering action, food clearance, preservation of tooth integrity, inhibition 
of bacterial colonization and activity, and mastication and swallowing [103].  Typically, the 
average healthy adult produces 0.5 to 1.5 L of saliva daily, with an approximate rate of 0.5 
ml/min [152].  
Saliva contains serum constituents and certain hormones that correlate to blood 
concentrations and therefore has high potential to mirror systemic conditions [102, 103].  Saliva 
harbors a wide spectrum of components, including steroid hormones and IgA, that enter the 
saliva from blood capillaries by passive diffusion of lipophilic molecules, ultrafiltration through 
gingival crevices, or through active transport of proteins via ligand-receptor binding [11, 153].  It 
has been shown that amines and peptides, such as melatonin and insulin, enter the saliva 
through these methods and exhibit an excellent correlation between saliva and blood 
concentrations [106].  Several aspects of saliva and ease of collection make it an ideal 
diagnostic fluid for disease and overall health surveillance particularly in comparison to serum or 
plasma.   
There has been an increase of interest in using saliva as a diagnostic medium over the past 
10 years [11].  Saliva does provide a true representation of overall health as the salivary glands 
are exocrine glands that produce strongly detectable protein profiles of health status at the 
moment of collection [11].  Progress has been made in the development of salivary biomarkers 
for indication of several diseases such as cardiovascular disease [154], oral cancer [155], and 
breast cancer [156].  Saliva’s use as a diagnostic fluid has been hindered due to a lack of 
understanding of biomolecules within saliva and their relevance to disease etiology, combined 
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with the diurnal/circadian variations of these biomolecules [11].  If saliva is to be utilized in the 
future as a non-invasive source of biomarkers indicating systemic disease, biological variation in 
association with diurnal rhythms must be demonstrated. 
There are some limitations to salivary research. Salivary composition is not constant and 
varies with changes in flow.  Saliva is composed of immunoglobulins, proteins, mucins, 
enzymes, and a variety of electrolytes all of which are multifunctional, redundant, and 
amphifunctional and contribute to the modulation of demineralization and remineralization of 
teeth, antimicrobial/antibacterial actions, oral microorganism activity of dental plaque 
metabolism, and oral pH [103].  In addition, the pH of saliva is not constant.  The typical pH of 
saliva is slightly acidic being 6 to 7, however, salivary flows may alter the pH depending on flow 
rate from 5.3 (low flow) to 7.8 (high flow) [103].  Furthermore, salivary flow rates fluctuate 
depending on circadian rhythms, which also affect the concentrations of salivary components, 
such as inflammatory cytokines and matrix metalloproteinases (MMPs).  
Inflammatory diseases, such as inflammatory bowel disease and rheumatoid arthritis (RA), 
have shown a clear association with diurnal rhythms [85, 157].  Circadian clock genes can be 
turned off by inflammatory mediators (i.e. TNF-α) or these genes can impact the intestinal 
epithelial cell permeability leading to inflammation [85].  In RA patients, cytokine-mediated 
inflammation fluctuates on a diurnal pattern of the release of melatonin and cortisol and joint 
symptoms are most severe in the early morning [83, 158].  Furthermore, the circadian system in 
the human body has many influences on aging and disease progression.  Significant disruption 
and aging in the circadian rhythms of the sleep-wake cycle can lead to the development of 
Alzheimer’s, Parkinson’s, and Huntington’s disease [159, 160].   
Increasing evidence supports a complex relationship between circadian rhythms and the 
regulation of both the innate and adaptive immune systems [86].  Circadian rhythm disruption 
has been shown to accelerate the progression of diabetes in mice [84].  A knockout of the 
circadian rhythm CLOCK genes, Arntl1 and Clock, led to the activation of the NF-κB pathway 
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and increased inflammation triggering the onset of diabetes, whereas the ablation of the clock 
gene, aryl hydrocarbon receptor nuclear translocator (ARNT), impaired insulin secretion, 
implemented abnormal glucose tolerance, and altered islet gene expression in mice [84].  In 
addition, there is evidence of the clock period circadian protein, PER3, length polymorphism in 
T2D patients [161]  
Previous literature has indicated that plasma cortisol and possibly melatonin seem to 
regulate diurnal variations of cytokine production [83].  One study demonstrated that salivary IL-
6 and C-reactive protein (CRP) levels peaked in the morning, but CRP remained constant while 
IL-6 peaked again at bedtime in 27 healthy individuals [162].  Circulating IL-6 and CRP levels 
showed similar trends indicating there could be a shared mechanism involving the regulation of 
diurnal patterns of cytokines in blood and saliva [162, 163].  Further research needs to be 
conducted to determine the impact of circadian rhythms on oral inflammation.  
 The human mouth is home to a diverse collection of bacteria, viruses, fungi, protozoa, and 
archaea, termed the oral microbiome, and consists of both pathogenic and commensal 
microbes [164].  For a variety of reasons, commensal microbes can become pathogenic or allow 
pathogens to colonize, leading to a disease state [164].  Little research has been done to 
investigate the variations in human responses to the oral microbiome and further research 
needs to be done to comprehend its role in the development of human diseases.  Additionally, 
no studies to date have comprehensively examined the diurnal rhythms of the oral microbiome 
from saliva within healthy subjects. 
To demonstrate biological variation within diurnal rhythms, we examined longitudinal saliva 
samples collected from healthy non-T1D donors and measured a panel of cytokines previously 
demonstrated to have potential diagnostic properties.  The diurnal rhythms of saliva have been 
examined in twelve healthy adults.  Samples were collected based on each individual’s sleep 
schedule.  In addition, we included commercial saliva (Innovative Research, Novi, MI) samples 
on each plate run to show consistency across plates.  
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To address this, we conducted an original study to examine the circadian rhythms of six 
inflammatory cytokine expressions within each individual.  We chose these six cytokines- IL-1β, 
IL-6, IL-8, IL-10, and TNF-α- since they play a role in the progression of diabetes, 
hyperglycemia, and/or glucose production or have been found to have high levels in 
periodontitis or T1D tissue [10, 58, 61, 63, 66, 68, 165].  It has been concluded that salivary 
cytokine concentration independently fluctuates based on diurnal rhythms.  Inflammation is 
generally highest in the early morning and late at night. 
 
Methods 
Participants 
Twelve healthy individuals aged 20-42 (mean age of 26.5) were recruited to participate 
in this study.  The sample consisted of seven females and five Caucasian males.  The mean 
body mass index of the participants was 23.08 kg/m2 and all but one were non-smokers.  None 
reported gross infections, immune disorders, or oral/dental disease, and none used any 
medications or dietary supplements that affect immune activity.  The study was reviewed and 
approved by the University of South Florida Institutional Review Board.  All participants provided 
informed written consent for participation in the study. 
 
Saliva Collection 
Saliva samples for IL-1β, IL-6, IL-8, IL-10, and TNF-α measurements were obtained.  
The participants were asked to passively drool into a 2 mL collection vial with an attached 
salivary collection aid (Saliva Biol LLC No. 61/524096 patent pending) over six time-points 
throughout the day based on each subject’s sleep schedule (Wake, Wake +30 minutes, Wake + 
3 hours, Wake + 6 hours, Wake + 9 hours, and Prior to Sleep).  Two of the subjects were asked 
to repeat this sampling procedure on 3 consecutive days to test the stability of the diurnal 
patterns.  The passive drool collection method is recommended by previous studies as it 
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provides the least interference with the salivary immunoassay results for the cytokines 
measured [162].  Unstimulated whole saliva often correlates to systemic clinical conditions more 
accurately than stimulated saliva, since materials used to stimulate flow may change salivary 
composition [166].  The collection vials contained a protease and phosphatase inhibitor cocktail 
(EDTA-free Thermo Scientific HaltTM, Thermos Fisher Scientific, Rockford, IL) at 1x to assist in 
the preservation of the saliva sample.  In general, sampling was performed at the participants’ 
homes with supplied and labeled tubes with instructions.   
Following collection, saliva samples were frozen in the participants’ home freezers and 
transported in insulated containers with ice-packs to laboratory following completion of the 
collected samples.  The sample was centrifuged for 5 minutes at 4000 rpm in a refrigerated 
centrifuge set at 4°C.  The saliva sample was then distributed into 100 µL aliquots and stored 
immediately at -80°C until multiplexing analysis.  Commercially received saliva (Innovative 
Research, Novi, MI) was also aliquoted and stored frozen to be later used within each 
multiplexing batch for the purpose of quality control. 
 
Procedures 
The participants were instructed to provide saliva samples 6 times throughout the day (at 
wake, +30 minutes from wake, +3 hours from wake, +6 hours from wake, +9 hours from wake, 
and bedtime).  The participants did not have to change their sleep/wake schedule for this study 
and each was encouraged to keep their normal sleep/wake routine.  Two of the participants 
were asked to repeat this sampling procedure on 3 consecutive days to test the stability of the 
diurnal patterns.  All participants were instructed to refrain from eating, drinking, heavy 
exercising, or brushing their teeth for 30 minutes after wakening and for 1 hour prior to each 
sampling time to eliminate effects of masticatory stimulation and reduce food debris.  Written 
instructions about the saliva collection protocol were distributed.  All participants completed an 
oral health questionnaire.  This questionnaire consisted of two questions regarding gingival 
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condition: 1) Compared to others your age, how would you rate the current condition of your 
gums: poor, fair, good, excellent, and 2) Do you have a loose tooth?  These questions were 
previously shown to be correlated with clinically determined periodontal health [56, 137]. 
 
Cytokine Analysis 
Cytokine levels were determined using a multiplexed bead immunoassay and measured 
with a Luminex Magpix® instrument (Luminex, Austin, TX).  Six cytokines: IL-1β, IL-6, IL-8, IL-
10, TNF-α, and IFN- were measured using the high sensitivity human cytokine magnetic bead 
assay (EMD Millipore, Cat. No. HSCYTMAG-28SK, Billerica, MA) following manufacturer 
instructions as described in Chapter 2.  Quality control samples of non-T1D saliva were included 
in duplicate in each assay run to account for any potential intra or inter-assay variability. 
 
Cotinine Analysis 
Salivary cotinine levels were measured utilizing a commercial ELISA (Salimetrics, 
Catalog Number 1-2002, Carlsbad, CA) according to manufacturer’s instructions as described in 
Chapter 2.  Cotinine levels (ng/mL) were determined from 20 µL of saliva and measured in 
duplicate.  A measurement greater than 25 ng/mL indicated that the subject was exposed to 
second-hand smoke or was smoking up to 4 days prior to collection.  Results are reported as 
means and standard deviations. 
 
ELISA Analysis 
Six cytokines- IL-1β, IL-6, IL-8, IL-10, and TNF-α – were analyzed using a Qiagen Multi-
Analyte ELISArray™ kit (Catalog Number MEH-004A, Valencia, CA) qualitatively.  The protocol 
was followed per manufacturer’s instructions as described in Chapter 2.  Sample Dilution Buffer 
2 was utilized and saliva samples were not diluted as recommended by Qiagen. 
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Results 
Participant Characteristics 
Table 5 displays the characteristics of the 12 subjects who participated in this study.  Table 
6 provides a summary of the twelve healthy subjects enrolled, as well as their metabolic 
parameters including BMI and self-reported periodontal condition.  We enrolled 5 Caucasian 
males, 2 Hispanic and 5 Caucasian females.  The mean age was 26.5 and the mean BMI was 
23.08 kg/m2.  None of the participants were considered obese or were taking any chronic 
medications for a documented medical condition.  The average amount of time for the “Prior to 
sleep” collection time was 16.08 hours.  The cotinine ELISA test showed that only one individual 
was considered to be exposed to second-hand smoke or was smoking on the day of collection.   
 
Total Salivary Protein Levels 
Total salivary protein was analyzed in each individual throughout the day at six different 
time-points (Figure 16) following the protocol from the BCA protein kit as previously described in 
Chapter 2.  The Tukey’s Multiple Comparison and One-way ANOVA tests show that there is a 
significant difference (p<0.05) in total protein content between “Wake” and all other time-points.  
The Two-way ANOVA test analyzed the total protein content of individual subject’s saliva 
throughout the day.  Nine out of the twelve subjects showed a statistical difference between 
“Wake” vs. “Prior to sleep” total salivary protein content. 
 
Diurnal Variations of Salivary Cytokines 
Saliva was collected from twelve healthy subjects during six time-points throughout the 
day based on each individual’s sleep schedule.  Additionally, commercially received quality 
control saliva was included on each plate and the mean levels are described in Figure 17.  As 
shown in Figures 20-25 and Table 7, diurnal patterns were unique to each individual, yet for 
certain individuals, all cytokine levels peaked at the same time-point.  Subject 01 was generally 
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inflamed in the evening, with the exception of IFN-γ, which was detectable in the middle of the 
day and IL-1β, which peaked in the morning (there were significantly higher cytokine levels at 
“W + 6 hours” compared to the “Wake” and “Prior to Sleep” time-point, with the exception of IL-
1β, which was higher at “Wake” than at ”W + 6 hours”).  In Subject 02, there were significantly 
higher cytokine levels in the morning, whereas Subject 08 showed higher cytokine levels 
immediately before going to sleep.  In Subject 03, cytokine levels were significantly higher at 
“Wake” than all other time-points and IFN-γ levels were undetectable.  Subjects 04 and 11 
demonstrated similar diurnal patterns in which all detectable cytokine levels were significantly 
higher at “Wake” with the exception of IL-10 and IL-6, respectively, which were most elevated at 
“Prior to Sleep”.  In Subject 05, cytokine levels were significantly higher at “Prior to Sleep” than 
“Wake”, with the exception of IL-8, which was lowest at “Wake +3 hours” and highest at “Wake 
+6 hours”.  There were mostly undetectable or no trend in cytokine levels for Subjects 06, 07, 
09, and 12.  In Subject 08, cytokine levels peaked at “Prior to Sleep”, with the exception of IFN-
γ, which peaked at “Wake + 9 hours” time-point.  In Subject 10, all cytokine levels were highest 
at “Wake + 9 hours” and/or “Prior to Sleep” time-points. 
Figure 18 and Figure 19 portray the diurnal patterns of all six cytokines throughout the 
day in all subjects combined.  IL-10 levels were significantly higher (p < 0.01) immediately 
before sleep than at wake for six subjects.  Inversely, IL-1β levels were significantly higher at 
wake than in the afternoon and evening for seven subjects.  IL-10, TNF-α, and IFN-γ were 
mostly undetectable, however six of the subjects expressed higher levels of IFN-γ in the 
evening.  Due to undetectable levels of certain time-points, ANOVA could not be performed for 
TNF-α and IFN-γ in all twelve subjects.  Subjects 01 and 12 were the only subjects to have 
detectable levels of IL-10 in all time-points.  There was a substantial error bar for IL-6 detection 
due to the fact that Subject 04 showed high levels of IL-6 (~400 pg/mL) at the “Wake” time-point 
compared to the rest of the subjects (~5 pg/mL).  Nonetheless, when dropping out these values 
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in the combined graph, there is no trend for IL-6 production.  To verify accurate results, an 
additional Luminex plate run was performed for Subjects 07-12.   
 
Consecutive Diurnal Patterns 
 To test for diurnal pattern stability, two subjects, Subject 01 and Subject 02, provided 
saliva samples for six time-points throughout each day for three consecutive days.  IL-1β and 
TNF-α were analyzed for the three consecutive day analysis since they demonstrated the 
strongest diurnal trends.  The trends were similar for each day: IL-1β and TNF-α levels were 
mostly elevated in the morning in each subject as shown in Figure 26 and Figure 27, 
respectively.  
 
Cotinine Analysis 
 Cotinine is a bi-product of nicotine and its levels can be detected up to 4 days for light 
smoking, 5 days for medium smokers, up to 10 days in heavy or addicted smokers, and for 
more than 10 days in people who chew tobacco [140].  Nicotine can only be detected up to 10 
hours in the saliva [140]; therefore we measured cotinine levels.  All twelve subjects were 
analyzed for smoking status through detection of cotinine in the saliva.  Only one subject 
(Subject 02) was exposed to or had been smoking up to 4 days prior to collection.  Figure 28 
demonstrates these results. 
 
ELISA and Luminex Magpix® Comparison 
Figure 29 compares the ELISA and Luminex Magpix® results using two healthy adult 
female subjects: Subject A and B.  These results have demonstrated the sensitivity of the 
Luminex assay and support our reasoning behind using the Luminex Magpix®.  The trends of 
cytokine expression have been confirmed in the ELISA.  Using an independent method shows 
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the same relative differences and relationships amongst cytokines, however as concentrations 
get lower, the ELISA method is unable to discriminate these relationships.  Although the same 
relationships are shown with ELISA, the Luminex is much more sensitive. 
 
Discussion 
This study investigated the diurnal patterns of salivary IL-1β, IL-6, IL-8, IL-10, IFN-γ, and 
TNF-α in healthy young adults.  Although previous studies demonstrated the diurnal variations 
of salivary IL-6 [162, 167], to our knowledge, this is the first study to simultaneously examine 
diurnal levels of IL-1β, IL-8, IL-10, and TNF-α throughout the day.  Cytokines have their own 
specific diurnal rhythms and their concentrations are typically highest in either the early morning 
or late night.  Generally speaking, there is a trend of an increase in expression of pro-
inflammatory (Th1) cytokines, such as IL-1β and TNF-α, in the morning and an increase in 
expression of anti-inflammatory (Th2) cytokines, such as IL-10, in the evening.   
We found that the levels of TNF-α and IL-1β remained elevated in the morning over 
three consecutive days.  To our knowledge, this is the first study to analyze these salivary 
cytokines over three consecutive days.  One study analyzed the diurnal patterns of salivary C-
reactive protein and IL-6 in healthy adults over two consecutive days revealing CRP levels to be 
more stable than IL-6 [162].  Yet, there is much more information needed to examine the daily 
patterns and stability of salivary cytokines. 
Studies have shown evidence of circadian rhythms having an impact on diabetes.  A 
previous study demonstrated hyperglycemic conditions from an impairment in glucose tolerance 
and insulin secretion when the pancreatic clock gene, BMAL1, is knocked down in mice [168].  
Knockdown of other clock genes, such as ARNT and CRY, have disclosed an abnormal glucose 
tolerance, increased inflammation, and altered islet gene expression in mice [84].  Another 
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study revealed that when diet-induced obesity is complimented with circadian disruption in male 
rats, β cells are impaired and subsequent type 2 diabetes occurs [169].   
There is a possibility that melatonin levels could affect the inflammation of cytokines 
since it has an anti-inflammatory effect by reduced expressions of iNOS, IL-1β, and IL-6 
activities [170].  This study revealed that melatonin suppressed acrolein-induced IL-8 production 
in human pulmonary fibroblasts.  Additionally, melatonin is suggested to play a role in restoring 
insulin resistance and impaired glucose intolerance derived from the disturbance of circadian 
rhythms [171].  This evidence further supports the importance of circadian rhythms in the 
development of diabetes. 
To date, there are no studies that investigate the daily variations of cytokines and 
chemokines in human saliva.  In a particular study, the daily variations of cytokines and 
chemokines in tears of healthy individuals were examined.  Concentrations of 18 analytes were 
measured using multiplexing technology and IL-10 levels were undetectable in the afternoon yet 
detectable only in the evening, whereas IL-6 and IL-1β levels were higher in the evening [172].  
This is somewhat consistent with our results in that most of the IL-10 levels were undetectable 
in the twelve subject cohort.  Additionally, six out the twelve subjects expressed higher IL-6 
levels in the evening hours, five out the twelve subjects expressed higher IL-1β levels in the 
evening.  In general, although we were mostly unable to detect IL-10, IFN-γ, and TNF-α levels, 
they still may have critical diagnostic value.  
 It is known that the diurnal rhythm of plasma cortisol creates a higher expression of pro-
inflammatory cytokines during the evening and a lower expression during the afternoon [173].  
Izawa et. al found that IL-6 levels peaked at awakening, gradually declined throughout the day, 
and then peaked again back at night, whereas CRP levels peaked at awakening and lowered 
throughout the day in 27 healthy individuals [162].  We saw similar concentrations of IL-6, 
however the trends varied most likely due to sample size.  This study analyzed salivary 
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cytokines from a sample size of individuals with the majority age being in the mid-20’s and a 
small number of participants, hence these findings should be further analyzed in larger samples. 
 These findings indicate that each individual has a unique pro- and anti-inflammatory 
diurnal pattern.  Circadian variability of inflammation is important for the approach of clinical 
relevance of inflammatory disease in addition to the optimization of clinical treatment times 
[174].  In previous reports, circadian rhythms of Th1 cytokines have been shown to peak during 
the morning and at night in rheumatoid arthritis patients, possibly due to changes in metabolism, 
and secretions of corticosteroids and plasma melatonin and cortisol [175].   
 The findings that salivary IL-8, IL-6, and IL-1β, levels had strong diurnal rhythms could 
be useful for investigating the pathway linking sleeping patterns and disease.  In addition, these 
results provide critical information of diurnal patterns to optimize salivary collection techniques.  
Environmental factors, such as cigarette/tobacco smoke have been found to disrupt circadian 
clock function causing an elevation in lung and peripheral blood mononuclear cell (PBMC) 
inflammation as well as lung destruction via the SIRT1-BMAL1 pathway [176, 177].  It was 
found that levels of IL-8, IL-6, and TNF-α in PBMCs were reduced in smokers compared to non-
smokers [177].  Therefore, circadian rhythms could potentially lead to a dysregulation in 
inflammation with regard to particular cytokines. 
 The discovery and validity of salivary biomarkers relies on the important factor of the 
method of saliva collection: stimulated versus unstimulated.  Stimulated saliva, primarily derived 
from the parotid glands, inserts bicarbonates that interfere with the composition of salivary 
components by diluting potential analytes and decreasing concentrations of salivary peroxidase, 
uric acid, sulfyhdryls, and secretory IgA [105].  Thus, stimulated saliva, primarily derived from 
the submandibular and sublingual glands, is optimal since it offers the least variance of salivary 
biomolecules. 
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Table 5: Subject Characteristics (n=12) 
 
Characteristics  
Age (years)* 26.5 (±5.2) 
Male (n)† 5 (41.7) 
Prior to Sleep collection time (hours) 16.08 
Race/ethnicity (n) †  
White 10 (83.3) 
Hispanic 2 (16.7) 
BMI (kg/m2)* 23.08 (±3.5) 
BMI category (n)†  
Underweight (<18.5  kg/m2) † 1 (8.3) 
Normal (18.5-<25 kg/m2) † 6 (50) 
Overweight (25-<30  kg/m2) † 5 (41.7) 
Obese (≥30 kg/m2) † 0 (0) 
Cotinine (ng/ml)‡ 5.12 
Current smoker (n; cotinine > 25 ng/ml)† 1 (8.3) 
*Data presented as mean ±SD 
  †Data presented as number (%) 
‡Data presented as geometric mean (25th-75th percentile) 
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Table 6: Healthy Subject Enrollment Log 
 
Subject # 
sample 
ID 
Time Race Sex Age BMI Gum Rating 
Loose 
tooth? 
Saliva 
Collected 
(mL) 
Tubes   
(100μL 
each) 
Amount of 
sleep on 
day of 
collection 
001 001 A 7:02 AM Caucasian F 25 27.5 Good no 1.5 4 8 
 
001 B 7:32 AM 
      
1.5 5 
 
 
001 C 10:33 AM 
      
1.8 10 
 
 
001 D 1:33 PM 
      
1.8 8 
 
 
001 E 4:28 PM 
      
1.8 12 
 
 
001 F 11:02 PM 
      
1.8 14 
 
Day 2 001 A 7:29 AM 
      
1.5 9 8 
 
001 B 8:00 AM 
      
1.5 8 
 
 
001 C 11:02 AM 
      
1.5 9 
 
 
001 D 2:02 PM 
      
1.5 6 
 
 
001 E 5:00 PM 
      
1.5 0 
 
 
001 F 12:21 AM 
      
1.5 9 
 
Day 3 001 A 9:18 AM 
      
1.8 8 8 
 
001 B 9:50 AM 
      
1.8 9 
 
 
001 C 12:50PM 
      
1.6 9 
 
 
001 D 3:50 PM 
      
1.8 10 
 
 
001 E 6:40 PM 
      
1.5 10 
 
 
001 F 12:00 AM 
      
1.5 10 
 
002 002 A 6:35 AM Caucasian M 24 28.7 Good no 1.8 9 7 
 
002 B 7:05 AM 
      
2 12 
 
 
002 C 9:34 AM 
      
1.3 7 
 
 
002 D 12:32 PM 
      
1.5 11 
 
 
002 E 3:37 PM 
      
1.9 13 
 
 
002 F 10:31 PM 
      
1.8 14 
 
Day 2 002 A 6:20 AM 
      
1.8 14 8 
 
002 B 6:50 AM 
      
1.8 13 
 
 
002 C 9:24 AM 
      
1.8 13 
 
 
002 D 12:36 PM 
      
1.3 7 
 
 
002 E 3:36 PM 
      
1.8 14 
 
 
002 F 10:52 PM 
      
1.8 11 
 
Day 3 002 A 6:20 AM 
      
1.8 13 7.5 
 
002 B 6:50 AM 
      
1.8 12 
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Subject # 
sample 
ID 
Time Race Sex Age BMI Gum Rating 
Loose 
tooth? 
Saliva 
Collected 
(mL) 
Tubes   
(100μL 
each) 
Amount of 
sleep on 
day of 
collection 
 
002 C 9:36 AM 
      
1.8 12 
 
 002 D 12:34 PM       1.3 7  
 
002 E 3:31 PM 
      
1.8 12 
 
 
002 F 10:48 PM 
      
1.8 13 
 
003 003 A 6:00 AM Caucasian M 42 23 Fair no 1.8 7 6 
 
003 B 6:30 AM 
      
1.25 5 
 
 
003 C 9:00 AM 
      
1.5 7 
 
 
003 D 12:00 PM 
      
1.8 8 
 
 
003 E 3:00 PM 
      
1.8 7 
 
 
003 F 12:00 AM 
      
1.8 10 
 
004 004 A 6:35 AM Caucasian F 29 18.8 Very Good no 1.6 6 7.5 
 
004 B 7:10 AM 
      
1.3 7 
 
 
004 C 10:11 AM 
      
1.25 6 
 
 
004 D 1:13 PM 
      
1.3 5 
 
 
004 E 4:16 PM 
      
1 5 
 
 
004 F 11:42 PM 
      
1.25 9 
 
005 005 A 9:30 AM Caucasian F 25 19.7 Very Good no 1.8 12 8.5 
 
005 B 10:00 AM 
      
1.8 13 
 
 
005 C 1:07 PM 
      
1.8 8 
 
 
005 D 4:07 PM 
      
1.5 6 
 
 
005 E 7:05 PM 
      
1.5 8 
 
 
005 F 10:06 PM 
      
1.5 8 
 
006 006 A 9:55 AM Caucasian F 24 27 Fair no 1.5 9 6 
 
006 B 10:25 AM 
      
1.5 12 
 
 
006 C 12:55 PM 
      
1.5 11 
 
 
006 D 3:55 PM 
      
1.5 11 
 
 
006 E 6:55 PM 
      
1.5 10 
 
 
006 F 2:05 AM 
      
1.5 11 
 
007 007A 9:00 AM Caucasian F 20 18.2 Excellent no 1.25 6 7 
 
007 B 9:30 AM 
      
1 6 
 
 
007 C 12:00 PM 
      
1.5 11 
 
 
007 D 3:00 PM 
      
1.4 9 
 
 
007 E 6:00 PM 
      
1.5 9 
 
 
007 F 11:30 PM 
      
1 5 
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Subject # 
sample 
ID 
Time Race Sex Age BMI Gum Rating 
Loose 
tooth? 
Saliva 
Collected 
(mL) 
Tubes   
(100μL 
each) 
Amount of 
sleep on 
day of 
collection 
008 008 A 6:55 AM 
      
1 3 
 
 008 B 7:30 AM       1.5 8  
 
008 C 11:15 AM 
      
1 5 
 
 
008 D 2:30 PM 
      
1 6 
 
 
008 E 5:30 PM 
      
1.5 7 
 
 
008 F 1:00 AM 
      
1 4 
 
009 009A 8:00 AM Caucasian M 22 25.77 Good no 1 3 7 
 
009 B 8:30 AM 
      
1.5 7 
 
 
009 C 11:30 AM 
      
1.5 7 
 
 
009 D 2:30 PM 
      
1 5 
 
 
009 E 5:28 PM 
      
1 6 
 
 
009 F 1:00 AM 
      
1 5 
 
010 010A 8:00 AM Caucasian M 26 21.1 Excellent no 1 6 6.5 
 
010 B 8:31 AM 
      
1.25 6 
 
 
010 C 11:35 AM 
      
1 6 
 
 
010 D 2:35 PM 
      
1 6 
 
 
010 E 5:35 PM 
      
1 6 
 
 
010 F 1:07 AM 
      
1.25 9 
 
011 011A 6:10 AM Hispanic F 26 22.3 Very Good no 1.5 7 6.5 
 
011 B 6:40 AM 
      
1 6 
 
 
011 C 9:10 AM 
      
1 5 
 
 
011 D 12:10 PM 
      
1 5 
 
 
011 E 3:10 PM 
      
1.5 5 
 
 
011 F 11:00 PM 
      
1 5 
 
012 011A 7:45 AM Caucasian F 27 19.7 Very Good no 1.25 6 7.5 
 
011 B 8:15 AM 
      
1.5 4 
 
 
011 C 10:45 AM 
      
1 5 
 
 
011 D 1:45 PM 
      
1 5 
 
 
011 E 4:45 PM 
      
1 7 
 
 
011 F 11:00 PM 
      
1 5 
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Figure 16: Total Protein Levels of Healthy Subjects’ Diurnal Saliva Samples 
Total protein content was determined using the BCA protein kit as previously described.  (A) 
The diurnal patterns of total salivary protein content (ng/mL) in healthy subjects by time of day.  
Protein levels were highest in the majority of subjects at the “Wake” time-point. (B) Total 
salivary protein content (ng/mL) in all healthy subjects combined (mean and SEM).  Error bars 
represent SEM.  There is a statistical difference (p<0.0001) between protein levels of Wake 
samples vs. all time-points.    
A 
B 
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Table 7: Cytokine Trends within Subjects Individually  
This table depicts the amount of significant difference compared to “wake” time-point for each 
subject and each cytokine. 
 
 
Data in red (†): ANOVA could not be performed; trends can be seen though.  N/A: all time-
points undetectable.  *: p<0.05, **: p<0.01, ***: p<0.0001. 
  
Subject # 01 02 03 04 05 06 07 08 09 10 11 12
IL-8
W+6 HIGHER 
(**)
All (***) 
LOWER 
No trend
All (***) 
LOWER 
W+3 LOWER (**), 
W+6 HIGHER (**)
All but W+30 
min. LOWER
All (***) 
LOWER 
W+30 min. 
(*), W+6, W+9 
(**) LOWER, 
Prior to Sleep 
(***) HIGHER 
W+30 min., 
W+6 (***), 
W+3 (*) 
LOWER
Prior to Sleep 
(***) HIGHER 
All LOWER 
(*)†
No trend
IL-6
W+6 HIGHER 
(***)
All 
undetectable 
or LOWER†
All 
undetectable 
or LOWER†
All (***) 
LOWER 
W+3 (*) LOWER, 
W+9 (*), Prior to 
Sleep (***) 
HIGHER
No trend/ 
undetectable
†
W+9 (*) 
HIGHER
Prior to Sleep 
HIGHER†
Prior to Sleep 
HIGHER†
W+9 (***), 
Prior to Sleep 
(*) HIGHER
Prior to Sleep 
HIGHER†
W+3 (***) 
HIGHER
IL-1β
Prior to Sleep 
(*) LOWER
All (***) 
LOWER 
All (***) 
LOWER 
All (***) 
LOWER 
W+30 min. (**), 
W+3 (***), W+9 
(**) LOWER, 
Prior to Sleep 
(***) HIGHER
All (***) 
LOWER 
All (***) 
LOWER 
Prior to Sleep 
HIGHER†
No trend/ 
undetectable
†
W+9, Prior to 
Sleep 
HIGHER†
All LOWER †
No trend/ 
undetectable
†
IL-10
W+6 (***), 
W+9 (**) 
HIGHER
No trend/ 
undetectable
†
All LOWER†
Prior to Sleep 
HIGHER†
Prior to Sleep 
HIGHER†
W+30 min., 
W+6 HIGHER†
W+6 HIGHER†
Prior to Sleep 
HIGHER†
W+9 HIGHER† W+9 HIGHER† All LOWER† N/A
TNF-α
W+6 , W+9 
HIGHER†
All 
undetectable 
or LOWER†
All 
undetectable 
or LOWER†
All LOWER†
Prior to Sleep 
HIGHER†
No trend/ 
undetectable
†
All 
undetectable 
or LOWER†
Prior to Sleep 
HIGHER†
N/A
Prior to Sleep 
HIGHER†
All 
undetectable 
or LOWER†
N/A
IFN-γ
W+3 HIGHER, 
rest 
undetectable
†
N/A N/A
All 
undetectable 
or LOWER†
Prior to Sleep 
HIGHER, rest 
undetectable†
N/A W+6 HIGHER† W+9 HIGHER† W+9 HIGHER† W+9 HIGHER†
No trend/ 
undetectable
†
All higher, W 
undetectable
†
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Figure 17: Mean Salivary Cytokine Levels in QC Saliva Samples   
A commercially received quality control saliva sample (Innovative Research, Novi, MI) was 
included on each plate (n=4) for the diurnal salivary cytokine analysis.  Mean cytokine levels 
were measured in these quality control samples with inhibitor to determine to demonstrate little 
inter-assay variability.  Error bars represent SEM. 
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Figure 18: Cytokine Salivary Levels of IFN-, IL-10, IL-1β, IL-6, IL-8, and TNF-α as 
Determined By Detected Levels 
Saliva was collected at various time-points throughout the day based on each individual’s sleep 
schedule. Each graph represents the mean undetectable and detectable levels of all 12 subjects 
combined (n=24).  IL-6, IL-1β, and TNF-α levels are generally highest in the morning, whereas 
IL-10 levels are generally higher in the evening.  In general, IL-10, TNF-α, and IFN-γ levels were 
either low or undetectable.  Error bars represent SEM.   
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Figure 19: Cytokine Salivary Trends of IFN-, IL-10, IL-1β, IL-6, IL-8, and TNF-α as 
Determined By Detected Levels in 12 Subjects Combined 
Saliva was collected at various time-points throughout the day based on each individual’s sleep 
schedule.  Each graph represents the mean undetectable and detectable levels of all 12 
subjects combined (n=24).  In general, IL-10, TNF-α, and IFN-γ levels were either low or 
undetectable. Error bars represent SEM.  IL-1β levels are significantly higher in the morning, 
whereas IL-10 levels are significantly higher in the evening.  All time-points are compared to 
Wake.  *: p<0.05, **: p<0.01, ***: p<0.0001.   
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Figure 20: Cytokine Salivary Levels of IL-8 (Mean and SEM) 
Saliva was collected at various time-points throughout the day based on each individual’s sleep 
schedule.  Subject 01 and Subject 02 graphs represent Day 3 saliva collection.  Each graph 
represents the detectable levels of IL-8 of each time-point in each subject.  Error bars represent 
SEM.  All time-points are compared to Wake.  *: p<0.05, **: p<0.01, ***: p<0.0001.   
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Figure 21: Cytokine Salivary Levels of IL-6 (Mean and SEM) 
Saliva was collected at various time-points throughout the day based on each individual’s sleep 
schedule.  Subject 01 and Subject 02 graphs represent Day 3 saliva collection.  Each graph 
represents the detectable levels of IL-6 of all time-points in each subject. Error bars represent 
SEM.  All time-points are compared to Wake.  *: p<0.05, **: p<0.01, ***: p<0.0001.    
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Figure 22: Cytokine Salivary Levels of IL-1β (Mean and SEM) 
Saliva was collected at various time-points throughout the day based on each individual’s sleep 
schedule.  Subject 01 and Subject 02 graphs represent Day 3 saliva collection.  Each graph 
represents the detectable levels of IL-1β of all time-points in each subject.  Error bars represent 
SEM.  All time-points are compared to Wake.  *: p<0.05, **: p<0.01, ***: p<0.0001.    
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Figure 23: Cytokine Salivary Levels of IL-10 (Mean and SEM) 
Saliva was collected at various time-points throughout the day based on each individual’s sleep 
schedule.  Subject 01 and Subject 02 graphs represent Day 3 saliva collection.  Each graph 
represents the detectable levels of IL-10 of all time-points in each subject.  Error bars represent 
SEM.  All time-points are compared to Wake.  *: p<0.05, **: p<0.01, ***: p<0.0001.    
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Figure 24: Cytokine Salivary Levels of TNF-α (Mean and SEM) 
Saliva was collected at various time-points throughout the day based on each individual’s sleep 
schedule.  Subject 01 and Subject 02 graphs represent Day 3 saliva collection.  Each graph 
represents the detectable levels of TNF-α of all time-points in each subject.  Undetectable levels 
are not shown in the graphs.  Error bars represent SEM. All time-points are compared to Wake.    
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Figure 25: Cytokine Salivary Levels of IFN- (Mean and SEM) 
Saliva was collected at various time-points throughout the day based on each individual’s sleep 
schedule.  Subject 01 and Subject 02 graphs represent Day 3 saliva collection.  Each graph 
represents the detectable levels of IFN-γ of all time-points in each subject.  Undetectable levels 
are not shown in these graphs.  Error bars represent standard error of the mean.  All time-points 
are compared to Wake.   
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Figure 26: Cytokine Salivary Levels of IL-1β Over Three Consecutive Days 
Saliva was collected at various time-points throughout the day based on each individual’s sleep 
schedule.  Each graph represents the detectable levels of IL-1β of all time-points in each 
subject.  Undetectable levels are not shown.  IL-1β levels are generally elevated in the morning 
on each day.  Error bars represent SEM.  
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Figure 27: Cytokine Salivary Levels of TNF-α Over Three Consecutive Days 
Saliva was collected at various time-points throughout the day based on each individual’s sleep 
schedule for 3 consecutive days.  Each graph represents the detectable levels of TNF-α of all 
time-points.  Undetectable levels are not shown.  TNF-α levels are generally elevated in the 
morning on each day.  Error bars represent SEM.  
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Figure 28: Cotinine Levels of 12 Healthy Subjects 
Unstimulated whole saliva was collected from 12 healthy subjects and their saliva was analyzed 
on 2 ELISA cotinine plates.  (A) Mean result of 7 subjects (performed in duplicate) from the 
subject range 01-07, (B) Mean result of 5 subjects (performed in duplicate) from the subject 
range 08-12.  The standard curve is represented by red diamonds and the blue dots indicate 
each individual saliva sample.  The standard curve ranged from 0.8 ng/mL to 200 ng/mL.  Any 
result greater than 25 ng/mL indicates a smoker or an involvement of second-hand smoke.   
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Figure 29: ELISA and Luminex Magpix® Cytokine Expression Comparison 
Saliva was collected from two healthy adult subjects and the trends of cytokine expression were 
confirmed in a qualitative ELISA.  A) ELISA results showed positive results IL-1β, IL-8, and IL-
10 for both subjects.  Detection below 1 pg/mL were considered negative, with the exception of 
IL-1β, in the ELISA experiment.  B) Luminex results demonstrated quantitative cytokine 
expression in pictogram measurements and is clearly more sensitive.  Significance was 
determined using Two-way ANOVA.  Error bars represent standard error of the mean.  
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Chapter 5: Impact of Hyperglycemia on the Inflammatory Profile from a Human 
Submandibular Gland Cell Line 
 
 
Abstract 
 The objective of this study is to address the gap in knowledge of salivary biomarkers of 
inflammation by measuring the distribution of select cytokines and MMPs previously 
demonstrated to have a putative causatory or protective role of T1D and periodontitis, 
respectively.  The presence and variation of nine different salivary biomarkers- IL-1β, IL-2, IL-4, 
IL-6, IL-8, IL-10, IL-13, IFN-γ, and TNF-α – and two MMPs–, MMP-8, and MMP-9- from the 
human submandibular gland cell (HSG) line will be described.  Biomarkers associated with 
distinct biological phases of periodontal disease (i.e. inflammation, collagen degradation, and 
bone remodeling) have been suggested to be useful for early recognition of patients with 
periodontitis [3].  The source of the increased salivary inflammatory burden is still being 
elucidated.  Therefore, we examined the inflammatory profile of HSG cells, one of the primary 
glands of saliva secretion.  Out of the eleven analytes analyzed, we found a significant increase 
of IL-13 (p<0.05) and IL-10 (p<0.05) in the HSG lysate from 5.5 mM to 22 mM glucose 
treatments.  This suggests that glucose stimulates an anti-inflammatory response within the 
submandibular salivary gland in vitro.  In addition, we discovered a significant decrease in IFN-γ 
(p<0.05) in the HSG lysate from 5.5 mM to 22 mM glucose treatments.  However, 
hyperglycemia does not grossly alter the inflammatory profile of the HSG cell line.  Oral Th1 
cytokines are potentially derived from other cell populations such as the liver. 
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Introduction 
There is a bi-directional relationship between periodontal health and diabetes– 
periodontal infection creates an inflammatory response that contributes to hyperglycemia 
whereas increase blood glucose levels initiates the development and prolongation of periodontal 
disease [178].  It all begins with inflammation from the dental plaque and its oral microbiome, 
which triggers hyperinflammation that causes alveolar bone to break down.  Both local and 
systemic inflammation occur via the periodontium and bacterial endotoxins, respectively.  Added 
sugar from the diet, as well as poor glycemic control, initiates an inflammatory cascade 
generating a chronic overexpression of pro-inflammatory cytokines and MMPs.  This, in turn, 
leads to inflammatory mediators acting as antagonists on insulin receptors generating insulin 
resistance [111] and stimulation of the liver to express CRP, serum amyloid A, and fibrogen, all 
of which contribute to hyperglycemia.  This hyperglycemic condition stimulates oxidative and 
other cellular stress increases free radicals, ROS, and the irreversible production of AGEs to 
instigate further inflammatory dysfunction contributing to inflammation of the oral mucosal 
tissues and potentially exacerbating periodontal disease [111, 178].   
The source of inflammation within the oral cavity occurs both locally and systemically 
[111], yet little is understood regarding the direct impact of glucose, either from the diet or 
chronic hyperglycemia, on the inflammatory profile of salivary cells.  Secretions from the salivary 
glands contain many proteins and peptides responsible for the maintenance of the oral cavity, 
rendering the submandibular, parotid, and sublingual cells to have a vital role in the progression 
and development of periodontal disease [179].  Recent evidence has suggested that 
inflammatory cytokines may originate from the serum, host immune system, salivary glands, 
and oral mucosal tissues [144].  Other studies have demonstrated that free fatty acids such as 
palmitate can increase IL-6 production from human salivary gland epithelial cells and certainly 
can immunologically contribute to the local milieu of the saliva [77].  However, the impact of 
glucose on cytokine-mediated inflammation has yet to be investigated in salivary gland cells.  
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Our results presented in chapter 3 revealed that oral inflammation was associated with glycemic 
control and therefore glucose may be serving as a dominant secretagogue of locally induced 
inflammation.  Thus, our goal is to even further identify and characterize the source of this 
inflammatory burden. 
Ultimately, there is a critical need for the comprehension of the secretory profile of these 
salivary cells since they may provide a constant source of basal inflammation and prolong the 
detrimental effects of periodontitis and diabetes.  To address this need, we characterized the 
immunological profile of the human submandibular gland (HSG) cell line, generously donated by 
Dr. Bruce Baum from the National Institute of Health/National Institute of Dental and Cranial 
Facial Research (NIH/NIDCR), under physiological and supraphysiological glucose and 
measured secreted cytokine levels.  We investigated this particular cell line due to the fact that 
the human submandibular gland is the largest contributor to salivary total content secretion 
[103].  We screened for several cytokines and proteins including MMP-9, MMP-8, IL-4, IL-2, IL-
13, IL-1β, IL-6, IL-8, IL-10, TNF-α, and IFN- and found that IL-13, IFN-γ, and IL-10 were 
associated with supraphysiological glucose.   
 
Materials and Methods 
Cell Culture 
 We examined the two dominant cell types responsible for saliva production: 
submandibular gland and parotid PSY gland cell lines.  The HSG cells were cultured as 
previously described in Chapter 2.  Six independent experiments in duplicated were performed 
for 24 glucose stimulation analysis, whereas three independent experiments in duplicate were 
performed for 48 hour and 72 hour glucose stimulation analysis.  We attempted to culture the 
human parotid PSY salivary gland cell line (American Type Culture Collection, CRL-7669 Hs 
917.T, Lot 58078722), however it was unsuccessful.  Despite several months of optimizing cell 
culture techniques and variations of media, the parotid cell line never reached confluency. 
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 To explore the possible additional sources of inflammation, we cultured BNL murine liver 
cells using the same procedures of cell culture as described in Chapter 2.  The BNL cells were 
stimulated with 5.5 mM, 11 mM, and 22 mM glucose concentrations over 24 hours. 
 
Cytokine and MMP Analysis 
Cytokine levels were determined using a multiplexed bead immunoassay and measured 
with a Luminex Magpix® instrument (Luminex, Austin, TX).  Eleven cytokines/MMPs: MMP-9, 
MMP-8, IL-4, IL-2, IL-13, IL-1β, IL-6, IL-8, IL-10, TNF-α, and IFN- were measured using the 
high sensitivity human cytokine magnetic bead assay (R&D Systems, Cat. No. LXSAHM, 
Minneapolis, MN, and EMD Millipore, Cat No. HSCYTMAG-60SK-06, Billerica, MA) following 
manufacturer instructions as discussed in Chapter 2.  All eleven cytokines and MMPs were 
analyzed on the 24 hour glucose stimulated plates, whereas six cytokines- IL-6, IL-8, IL-10, IL-
1β, TNF-α, and IFN-γ- were analyzed on the 48 hour and 72 hour glucose stimulated plates. 
 
Results 
Total Lysate and Media Protein Levels 
Figure 42 demonstrates that the total protein content of the BNL lysate remained 
consistent across all glucose treatments.  The total protein content of the HSG lysate remained 
consistent across all glucose treatments.  There was an increase in protein content of the HSG 
media samples as the concentration of glucose increased (Figure 30).  Regardless, the variance 
of cytokine levels suggests the increase in IL-13 is not due to protein content.  When using 200 
µL of MPER to lyse the cells, the protein content was too dilute as shown in Figure 30.  
Therefore, a repeat experiment of 24 hour, 48 hour, and 72 hour glucose treatment was 
performed and half the amount of MPER (100 µL) was applied to the HSG cells and collected 
(Figure 31).  The protein content increased significantly from 500 µg/mL to 1500 µg/mL.  
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Glucose Stimulation of HSG Cell Culture 
To initially determine the impact of glucose on changes in the inflammatory profile (IL-2, 
IL-4, IL-6, IL-8, IL-10, IL-13, IL-1β, TNF-α, IFN-γ, MMP-8, and MMP-9), we examined the HSG 
cell line.  Glucose was administered over 24, 48, and 72 hour time-courses and the 
inflammatory profile was investigated in both the media and cell lysate.  Th1 cytokine levels 
were unaffected by increased glucose concentration for 24 hours in both HSG cell lysate and 
media as demonstrated in Figure 32 and Figure 33, respectively.  IFN-γ levels were 
undetectable in the media of 24 hour glucose stimulation.  Th2 cytokine levels, with the 
exception of IL-13, were unaffected by increased glucose concentrations for 24 hours in both 
HSG cell lysate and media as shown in Figure 34 and Figure 35, respectively.  IL-13 
significantly increased (p<0.05) from basal conditions to 22mM glucose stimulation.  MMP-8, 
MMP-9, and IL-8 did not exhibit a significant trend as glucose levels increased in both HSG cell 
lysate and media as shown in Figure 36 and Figure 37, respectively.   
We measured 6 cytokines in the 48-hour and 72-hour glucose treated HSG cell lysate 
and media.  No significant trends were demonstrated in either the 48 hour glucose stimulated 
media or lysate (Figure 38 and Figure 39).  IFN-γ levels were undetectable in the media of 48 
hour and 72 hour glucose stimulation.  There was a significant decrease in IFN-γ levels in 72 
hour glucose stimulated lysate compared to basal conditions (Figure 40).  There were no 
significant trends in the 72 hour glucose stimulated media (Figure 41).  Multiplexing analysis 
revealed out of the eleven analytes, IL-13 and IL-10 levels were significantly elevated (p<0.05) 
and IFN-γ levels significantly decreased (p<0.05) as the concentration of glucose increased.  
Additionally, IL-8 levels decreased, but not significantly, at hyperglycemic conditions (22 mM) for 
24 hours in HSG cell media and for 48 hours in HSG cell lysate.   
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IL-13 Analysis 
We attempted to verify these results using an ELISA assay (Catalog number D1300B, 
R&D Systems Inc., Minneapolis, MN) per manufacturer’s instructions as described in Chapter 2.  
Yet, the antibody to IL-13 was not sensitive enough for detection in our samples.  Additionally, a 
Western Blot using a human IL-13 antibody (Catalog number AF-213-SP, R&D Systems Inc., 
Minneapolis, MN) was performed (as described in Chapter 2); however the antibody was not 
sensitive enough to detect cell lysate (53 µg/mL) despite protocol enhancements.  This further 
validates the high sensitivity of the Luminex Magpix® method. 
 
Glucose Stimulation of BNL Cell Culture 
To determine the impact of glucose on changes in the inflammatory profile of other 
sources (IL-6, IL-8, IL-10, IL-1β, TNF-α, and IFN-γ), we examined the BNL cell line.  Glucose 
was administered over a 24 hour time-course and the inflammatory profile was investigated in 
the cell lysate.  There was a significant increase in TNF-α levels from 5.5 mM to 22 mM glucose 
stimulation, as shown in Figure 43.  This suggests that the liver is a potential source of Th1 
cytokine inflammation under hyperglycemic conditions. 
 
Discussion 
This is the first study to explore the inflammatory profile of hyperglycemic conditions of 
salivary submandibular gland cells.  We identified that upon glucose stimulation, pro-
inflammatory cytokines, such as IFN-γ and IL-13, decrease, whereas anti-inflammatory 
cytokines, such as IL-10, increase.  Thus, hyperglycemic conditions may promote an anti-
inflammatory profile of the HSG cell line.  The majority of studies exploring the cytokine 
expressions of salivary gland cells often investigate inflammation associated with Sjögren's 
Syndrome (SS).  One study compared IL-10 and IL-13 levels in biopsied salivary gland 
homogenates and peripheral blood mononuclear blood cells (PBMC) of SS and healthy subjects 
 106 
and discovered expression of both cytokines in SS salivary gland samples and little to no 
expression in healthy controls, whereas only IL-13 gene expression was present in PBMC of SS 
subjects [180].  These results suggest a network of cytokines contributing to inflammation in a 
systemic and localized fashion.  
Submandibular gland cells do not appear to be a significant source of glucose induced 
inflammatory cytokine production.  The source of inflammation could potentially be derived from 
other sources, such as neutrophils.  Hyperglycemia affects the cytokine expression of BNL cells.  
Our results suggest that oral Th1 cytokines are potentially derived from other cells populations, 
such as the liver.   
The purpose of this study was to examine the direct impact of glucose on cells producing 
saliva.  Added sugar from the diet, as well as poor glycemic control, initiates an inflammatory 
cascade generating a chronic overexpression of pro-inflammatory cytokines [178].  In one 
particular study, the effects of glucose-induced hyperglycemia on human monocytic cells was 
analyzed.  They discovered a significant increase (2 to 5-fold) in the mRNA expression of TNF-α 
and IL-1β [181].  The source of inflammation under glucose-induced hyperglycemia in the oral 
milieu has yet to be extensively studied.  This study provides an increased understanding of the 
inflammatory profile within HSG cells under glucose-stimulated conditions. 
Another study analyzed the immunohistochemical expressions of salivary cytokines in 
lymphocytic infiltrates and epithelial cells of NOD versus BALB/c submandibular glands and 
found that cytokine expression was greatest in NOD mice, suggesting that this expression is 
involved in the development of organ-localized autoimmunity in the salivary glands of NOD mice 
[182].  However, the cytokine expression levels of human submandibular glands have yet to be 
analyzed.  
Limited studies have examined the effects of hyperglycemia on specific cellular 
populations within the mouth.  In a particular study, pharmacological inhibition of p38 MAPK or 
NF-κB, but not JNK, significantly suppressed palmitate-induced IL-6 secretion in human parotid 
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gland epithelial cells, suggesting that IL-6 secretion is induced through activation of said 
pathways [77].  Therefore, our next objective is to investigate the stress pathways activated 
from the increased expression of oral Th1 cytokines within HSG and BNL cells.  
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Figure 30: Protein Levels of 24 hour Glucose Stimulation of HSG Media and Cell Lysate 
Using 200 µL of MPER 
This graph demonstrates the combined levels of 3 independent experiments of 24 hour glucose 
treatments in duplicate (n=6).  Total protein content was determined using the BCA protein kit 
as previously described.  There are no significant differences amongst glucose treatments for 
both cell lysate, however there is a statistical difference (p<0.001) between protein content of 
the media and glucose concentration.  The error bars are represented by the standard error. 
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Figure 31: Protein Levels of Glucose Stimulation of HSG Media and Cell Lysate Using 100 
µL of MPER 
(A) This graph shows the HSG lysate levels of each glucose treatment of 24, 48, and 72 hours 
(n=3).  (B) This graph shows the HSG media levels of each glucose treatment of 24, 48, and 72 
hours (n=3).  Three independent experiments of each glucose stimulation were performed in 
duplicate.  The error bars are represented by the standard error.  Total protein content was 
determined using the BCA protein kit as previously described in Chapter 2. 
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Figure 32: Th1 Cytokine Levels of 24 Hour Glucose Stimulation of HSG Cell Lysate 
Human submandibular gland cells (HSGs) were starved for five hours in glucose-free medium 
and treated with 5.5 mM, 11 mM, and 22 mM concentrations of glucose over 24 hours, in six 
independent experiments in duplicate.  Cell lysate was collected using 200 µL of MPER and Th1 
cytokine levels were measured via Luminex Magpix®.  No significant trends were observed 
amongst various treatments.  Error bars represent standard error of the mean.  
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Figure 33: Th1 Cytokine Levels of 24 Hour Glucose Stimulation of HSG Cell Media 
Human submandibular gland cells (HSGs) were starved for five hours in glucose-free medium 
and treated with 5.5 mM, 11 mM, and 22 mM concentrations of glucose over 24 hours, in six 
independent experiments in duplicate.  MMP-8, MMP-9, and IL-8 levels in the media were 
measured via Luminex Magpix®.  No significant trends were observed amongst various 
treatments.  A Two-way ANOVA could not be performed due to undetectable levels of several 
data points.  IFN-γ was completely undetectable in HSG media.  Error bars represent standard 
error of the mean. 
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Figure 34: Th2 Cytokine Levels of 24 Hour Glucose Stimulation of HSG Cell Lysate 
Human submandibular gland cells (HSGs) were starved for five hours in glucose-free medium 
and treated with 5.5 mM, 11 mM, and 22 mM concentrations of glucose over 24 hours, in six 
independent experiments in duplicate.  Cell lysate was collected using 200 µL of MPER and Th2 
cytokine levels were measured via Luminex Magpix®.  IL-13 showed a significant increase 
(p<0.05) in expression from 5.5 mM to 22 mM glucose treatment.  Error bars represent standard 
error of the mean.  
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Figure 35: Th2 Cytokine Levels of 24 Hour Glucose Stimulation of HSG Cell Media 
Human submandibular gland cells (HSGs) were starved for five hours in glucose-free medium 
and treated with 5.5 mM, 11 mM, and 22 mM concentrations of glucose over 24 hours, in six 
independent experiments in duplicate.  Th2 cytokine levels were measured via Luminex 
Magpix®.  No significant trends were observed amongst various treatments.  IL-10, IL-13, and 
IL-4 levels were all undetectable amongst all glucose treatments.  Error bars represent standard 
error of the mean.   
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Figure 36: MMP and Chemokine Levels of 24 Hour Glucose Stimulation of HSG Cell 
Lysate 
Human submandibular gland cells (HSGs) were starved for five hours in glucose-free medium 
and treated with 5.5 mM, 11 mM, and 22 mM concentrations of glucose over 24 hours, in six 
independent experiments in duplicate.  Cell lysate was collected using 200 µL of MPER and 
MMP-8, MMP-9, and IL-8 levels were measured via Luminex Magpix®.  No significant trends 
were observed amongst various treatments. Error bars represent standard error of the mean. 
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Figure 37: MMP and Chemokine Levels of 24 Hour Glucose Stimulation of HSG Cell 
Media  
Human submandibular gland cells (HSGs) were starved for five hours in glucose-free medium 
and treated with 5.5 mM, 11 mM, and 22 mM concentrations of glucose over 24 hours, in six 
independent experiments in duplicate.  MMP-8, MMP-9, and IL-8 levels in the media were 
measured via Luminex Magpix®.  No significant trends were observed amongst treatments.  
Error bars represent standard error of the mean.  IL-8 levels of 22 mM glucose treatment were 
mostly undetectable, hence a two-way ANOVA could not be performed.  
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Figure 38: Cytokine Levels of 48 Hour Glucose Stimulation of HSG Cell Lysate 
Human submandibular gland cells (HSGs) were starved for five hours in glucose-free medium 
and treated with 5.5 mM, 11 mM, and 22 mM concentrations of glucose over 48 hours, in three 
independent experiments in duplicate.  Cell lysate was collected using 200 µL of MPER and 
cytokine levels were measured via Luminex Magpix®.  Although no significant trends were 
observed, IL-8 levels tend to decrease when comparing basal to hyperglycemic conditions.  
Error bars represent standard error of the mean. 
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Figure 39: Cytokine Levels of 48 Hour Glucose Stimulation of HSG Cell Media 
Human submandibular gland cells (HSGs) were starved for five hours in glucose-free medium 
and treated with 5.5 mM, 11 mM, and 22 mM concentrations of glucose over 48 hours, in three 
independent experiments in duplicate.  IL-1β and IFN-γ levels were mostly undetectable.  No 
significant trends were observed amongst various treatments.  Error bars represent standard 
error of the mean. 
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Figure 40: Cytokine Levels of 72 Hour Glucose Stimulation of HSG Cell Lysate 
Human submandibular gland cells (HSGs) were starved for five hours in glucose-free medium 
and treated with 5.5 mM, 11 mM, and 22 mM concentrations of glucose over 72 hours, in three 
independent experiments in duplicate.  Cell lysate was collected using 200 µL of MPER and 
cytokine levels were measured via Luminex Magpix®.  IFN-γ was significantly decreased 
(p<0.05) from basal to hyperglycemic conditions.  Error bars represent standard error of the 
mean. 
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Figure 41: Cytokine Levels of 72 Hour Glucose Stimulation of HSG Cell Media 
Human submandibular gland cells (HSGs) were starved for five hours in glucose-free medium 
and treated with 5.5 mM, 11 mM, and 22 mM concentrations of glucose over 72 hours, in three 
independent experiments in duplicate.  IL-10 levels significantly increased (p<0.05) from basal 
to hyperglycemic conditions.  IL-1β levels were mostly undetectable across all glucose 
treatments.  Error bars represent standard error of the mean. 
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Figure 42: Protein Levels of 24 Hour Glucose Stimulation of BNL Cell Lysate Using 300 
µL of MPER 
This graph represents a single experiment of 24 hour glucose treatments in duplicate.  Total 
protein content was determined using the BCA protein kit as previously described.  There are no 
significant differences amongst glucose treatments.  The error bars are represented by the 
standard error. 
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Figure 43: Cytokine Levels of 24 Hour Glucose Stimulation of BNL Cell Lysate 
Mouse liver cells (BNLs) were starved for five hours in glucose-free medium and treated with 
5.5 mM, 11 mM, and 22 mM concentrations of glucose over 24 hours, in an experiment in 
duplicate.  Cytokine levels were measured via Luminex Magpix®.  There was a significant 
increase in TNF-α (p<0.05) as glucose levels increased.  No significant trends were observed in 
the other cytokines using a T-test.  Error bars represent standard error of the mean. 
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Conclusions and Future Directions 
 
 
Conclusions 
My dissertation is the first study to examine and describe the anticipated relationship 
between glycemic control and oral inflammation.  Through use of multiplexing analysis, we 
revealed that specific salivary inflammatory markers, such as MMP-8, MMP-9, and TNF-α, in 
T1D subjects are associated with decreased glycemic control and self-reported gingival 
condition.  We examined the saliva of 144 T1D subjects and found an association of oral 
inflammation with both HbA1c and periodontal status. 
Using high sensitivity multiplexing kits, we were able to analyze the specific circadian 
rhythms of six cytokines: IL-1β, IL-6, IL-8, IL-10, TNF-α, and IFN-γ in twelve healthy subjects 
over six different time points throughout the day.  Little is known on the impact of altered 
rhythms in oral inflammation and no studies to date have examined simultaneous 
measurements of numerous cytokines.  We revealed that salivary inflammatory markers have 
unique diurnal patterns and may affect the overall inflammatory response.  Cytokines have their 
own specific diurnal rhythms and their concentrations are typically highest in either the early 
morning or late night.  Generally speaking, there is a trend of an increase in expression of pro-
inflammatory (Th1) cytokines, such as IL-1β and TNF-α, in the morning and an increase in 
expression of anti-inflammatory (Th2) cytokines, such as IL-10, in the evening. 
We examined the inflammatory profile of eleven analytes in the human submandibular 
gland cell line to determine the source of oral inflammation.  Glucose stimulation in 
concentrations of 5.5 mM, 11 mM, and 22 mM was applied over 24, 48, and 72 hours.  This is 
the first study to explore the hyperglycemic conditions of human salivary glands.  
Submandibular gland cells do not appear to be a significant source of glucose-induced 
 123 
inflammatory cytokine production.  Although the source of inflammation is not from the human 
submandibular gland cells themselves, it could potentially be from other sources such as 
neutrophils.  The oral Th1 cytokines are potentially derived from other cell populations, such as 
the liver.  Overall, upon glucose stimulation, pro-inflammatory (Th2) cytokines, such as IFN-γ 
and IL-13, tend to decrease, whereas anti-inflammatory (Th1) cytokines, such as IL-10, tend to 
increase.  Hyperglycemic conditions may promote an anti-inflammatory profile of human 
submandibular gland cells.  
Diabetic complications and blood glucose levels are negatively affected by periodontal 
infection, however the evidence is scarce [178].  There are several risk factors for diabetes and 
periodontitis, including age, genetics, obesity, smoking, stress, diet, viruses, and smoking [178].  
Figure 44 summarizes the overall relationship between diabetes periodontal disease, circadian 
rhythms and oral inflammation.  There is a bi-directional relationship between periodontal health 
and diabetes– periodontal infection creates an inflammatory response that contributes to 
hyperglycemia whereas increase blood glucose levels initiates the development and 
prolongation of periodontal disease [178]. 
It all begins with inflammation from the dental plaque and its oral microbiome, which 
triggers hyperinflammation that causes alveolar bone to break down.  Both local and systemic 
inflammation occurs via the periodontium and bacterial endotoxins, respectively.  Added sugar 
from the diet, as well as poor glycemic control, initiates an inflammatory cascade generating a 
chronic overexpression of pro-inflammatory cytokines and MMPs.  This, in turn, leads to 
inflammatory mediators acting as antagonists on insulin receptors generating insulin resistance 
[111] and stimulation of the liver to express CRP, serum amyloid A, and fibrogen, all of which 
contribute to hyperglycemia.  This hyperglycemic condition stimulates oxidative and other 
cellular stress increases free radicals, ROS, and the irreversible production of AGEs to instigate 
further inflammatory dysfunction contributing to inflammation of the oral mucosal tissues and 
potentially exacerbating periodontal disease [111, 178].   
 124 
Despite this bidirectional relationship, little is known on the association between glucose 
control and oral inflammation as well as diurnal variation and the source of inflammation.  
Therefore, we investigated generalized inflammation within the mouth over a 24 hour time 
course and discovered IL-13 increases as hyperglycemic conditions occur in human 
submandibular gland cells.  Diurnal fluctuations of cytokine expression must be considered 
when analyzing salivary inflammation.  Generally speaking, inflammation occurs primarily in the 
morning and night indicating hormonal influences on salivary inflammation.  The alterations of 
inflammatory cytokines, MMPs, and chemokines might explain the variations of the oral 
environment during the day.  The source of this inflammation is predominately systemic rather 
than localized within the salivary milieu.  Overall, these results demonstrate the efficacy and 
potential utility of potential diagnostic salivary analysis of novel noninvasive biomarkers 
predictive of the progression and control of T1D. 
 
Future Directions 
The search for reliable biomarkers of type 1 diabetes continues.  TEDDY has started 
actively collecting peripheral blood mononuclear cells (PBMC) in high risk children in May 2010 
to study serum proteins as inflammatory or autoimmunity markers [35].  Advancements in this 
project will increase our understanding for discovering a potential breakthrough in the 
progression and diagnosis of diabetes.   
Our findings that diurnal rhythms of cytokines do exist and have distinctive patterns pave 
the pathway in understanding the biological basis of these markers.  Yet, the growth of salivary 
diagnostics has been impeded due to lack of sensitive detection methods, poor understanding 
of the biomolecular flow of proteins and hormones from the blood into the saliva, and circadian 
variations within saliva [183].  As newer, more sensitive assays are developed and further 
explorations of circadian rhythms of biomolecules within the saliva are completed, we could 
transition the discoveries of disease biomarkers to a clinical practice. 
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Our study has suggested that the salivary inflammatory burden may also be an 
indication of glycemic status or clinical management in T1D.  These data can be further utilized 
to establish novel clinical diagnostic tools to promote patient compliance and enhance 
subsequent clinical application of interventional therapy.  In addition, oral inflammatory burden 
with biomarkers described in this publication may also be combined with other biomarkers (i.e. 
autoantibodies in the case of T1D) either circulating or from the saliva that can be implemented 
to generate predictive models to identify subjects in the early stages of either developing 
autoimmunity or glucose intolerance. 
Limited studies have examined the effects of hyperglycemia on specific cellular 
populations within the mouth.  In a particular study, pharmacological inhibition of p38 MAPK or 
NF-κB, but not JNK, significantly suppressed palmitate-induced IL-6 secretion in human parotid 
gland epithelial cells, suggesting that IL-6 secretion is induced through activation of said 
pathways [77].  Therefore, our next objective is to investigate the stress pathways activated 
from the increased expression of oral Th1 cytokines within HSG cells.  Additionally, to broaden 
our comprehension of the source of inflammation, the investigation and analysis of activated 
stress pathways within additional cell populations, such as the liver, needs to be implemented. 
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Figure 44: Relationship of Diabetes, Periodontal Disease and Oral Inflammation 
Oral inflammation contributes to periodontal disease and diabetes via numerous factors as 
listed.  Time of collection is important due to the variation of cytokine and chemokine diurnal 
rhythms.  Exogenous sugar from the diet contributes to oral inflammation through production of 
AGEs and increased cytokine expression creating an insulin resistance.  Periodontal disease 
contributes to diabetes through the increased expression of MMPs leading to increased 
expression of cytokines.  Lastly, one of the major causes of diabetes is hyperglycemia, which in 
turn, can lead to oral inflammation. 
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Appendix A: Copyright Permission 
  
9/24/2015 University of South Florida Mail - Inquiry of Copyright 
 
                                                                                                     Melanie  K <mkuehl@mail.usf.edu> 
Inquiry of Copyright 
2 messages 
 
 
Melanie K <mkuehl@mail.usf.edu> 
To: plos@plos.org 
Fri, Sep 11, 2015 at 11:23 AM 
 
To whom it may concern: 
My name is Melanie Kuehl and I am a graduate student at the University of South Florida.  I have published a 
first author paper in Plos One earlier this year entitled, "Tumor Necrosis Factor-a, Matrix-Metalloproteinases 8 
and 9 Levels in the Saliva Are Associated with Increased Hemoglobin A 1c in Type 1 Diabetes Subjects".  May I 
have permission to use this article in my PhD dissertation for publication? 
Thank you, 
Melanie Kuehl 
 
 
 
PLOS <PLOS@plos.org> 
To: Melanie K <mkuehl@mail.usf.edu> 
Fri, Sep 11, 2015 at 1:50 PM 
 
Dear Melanie, 
 
 
 
Thank you for your enquiry. 
 
 
 
We are an open access publisher and as such everything we publish is freely available online throughout the world, for you to read, 
download, copy, distribute, and use (with attribution) any way you wish. 
 
 
 
No permission required. 
 
 
 
For information on the Creative Commons Attribution License please follow this link http://www.plos.org/about/open- 
access/license/ 
 
 
 
 
 
Hope this is helpful. 
 
 
 
 
 
Thank you, 
 
Tamaira  Witherspoon 
 
PLOS 
 
11  September2015 
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Appendix B: Consent Form for Salivary Biomarkers of Inflammation in Type 1 Diabetes 
 
Study ID:Ame2_Pro00009518 Date Approved: 2/25/2013 Expiration Date: 10/15/2013 
 
 
 
 
 
 
Informed Consent to Participate in Research 
Information to Consider Before Taking Part in this Research Study 
 
IRB Study # Pro00009518 
 
 
You are being asked to take part in a research study. Research studies include only people who choose 
to take part. This document is called an informed consent form. Please read this information carefully 
and take your time making your decision. Ask the researcher or study staff to discuss this consent form 
with you, please ask him/her to explain any words or information you do not clearly understand. We 
encourage you to talk with your family and friends before you decide to take part in this research 
study. The nature of the study, risks, inconveniences, discomforts, and other important information 
about the study are listed below. 
Please tell the study doctor or study staff if you are taking part in another research study. 
We are asking you to take part in a research study called: 
Salivary Biomarkers of Inflammation in Type 1 Diabetes 
 
The person who is in charge of this research study is Amy Alman, PhD. This person is called the 
Principal Investigator. However, other research staff may be involved and can act on behalf of the 
person in charge. 
 
All research for this study will be conducted at the University of South Florida Morsani Center for 
Advanced Health Care, the USF College of Public Health, and the USF Department of Cell Biology, 
Microbiology and Molecular Biology. 
 
 
 
 
Purpose of the study 
The purpose of this study is to: 
 Describe the presence of markers of inflammation in the saliva of adults with type 1 diabetes 
 Determine if these markers are associated with glycemic control 
 
Study Procedures 
If you take part in this study, you will be asked to: 
 Provide a saliva sample by passively drooling into a collection vial 
 Answer two questions about your oral health 
 Participation will take about 5-10 minutes of your time and can be completed at this clinic visit 
 
 
IRB Number:Pro00009518   
IC Adult Minimal Risk - Med Rev:9-3-2010 
IRB Consent Rev. Date:2/20/2013 
Page 1 of 6 
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IRB Number:Pro00009518           
IC Adult Minimal Risk - Med Rev:9-3-2010 
IRB Consent Rev. Date:2/20/2013 
Page 2 of 6 
 
 Your current BMI, hemoglobin A1c (a measure of glycemic control), duration of diabetes, race, 
gender, and age will be recorded from your medical record as a part of this study 
 We will not record your name, address, phone number, or any other identifying information 
 
Total Number of Participants 
About 150 individuals will take part in this study at USF. 
 
Alternatives 
You do not have to participate in this research study. 
 
Benefits 
We are unsure if you will receive any benefits by taking part in this research study. 
 
Risks or Discomfort 
This research is considered to be minimal risk. That means that the risks associated with this study are 
the same as what you face every day. There are no known additional risks to those who take part in 
this study. 
 
Compensation 
You will receive no payment or other compensation for taking part in this study. 
 
Cost 
There will be no additional costs to you as a result of being in this study. However, routine medical 
care for your condition (care you would have received whether or not you were in this study) will be 
charged to you or your insurance company. You may wish to contact your insurance company to 
discuss this further. 
 
Authorization to Use and Disclose Protected Health Information 
Who will see your health information? 
In this research study, we use and share your health information to the extent authorized (permitted) by 
you. We know that this information is private. The federal privacy regulations of the Health Insurance 
Portability & Accountability Act (HIPAA) protect your identifiable health information. If you 
authorize us to use your information we will protect it as required by the law. 
This research is conducted at the University of South Florida (USF). By signing this form, you are 
permitting USF to use personal health information collected about you for research purposes within the 
USF health care system. You are also allowing USF to share your personal health information with 
individuals or organizations other than USF who are also involved in the research and listed below. 
Who will disclose (share), receive, and/or use your information? 
To conduct this research, USF and the people and organizations may use or share your information. 
They may only use and share your information: 
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IC Adult Minimal Risk - Med Rev:9-3-2010 
IRB Consent Rev. Date:2/20/2013 
Page 3 of 6 
Study ID:Ame2_Pro00009518 Date Approved: 2/25/2013 Expiration Date: 10/15/2013 
 
 
 
 
 With the people and organizations on this list; 
 With you or your personal representative; and 
 As allowed by law. 
In addition to the people and organizations listed below in the Privacy and Confidentiality section of 
this document, the following groups of people may also be able to see information about you and may 
use the information to conduct the research: 
 The medical staff that takes care of you and those who are part of this research study; 
 Each research site for this study. This includes the research and medical staff at each site and 
USF; 
 Any laboratories, pharmacies, or other individuals and organizations that use your health 
information as part of the approved plan for this study; 
 The designated peer review committees such as the Protocol Review and Monitoring 
Committee; 
Who else can use and share this information? 
Anyone listed above may use consultants in this research and for the purpose of this study, may share 
your information with them. If you have questions about who they are, you should ask the study team. 
Individuals who receive your health information for this research study may not be required by the 
HIPAA Privacy Rule to protect it and may share your information with others without your 
permission. They can only do so if permitted by the laws governing them. For example, the study 
sponsor may share your information with others. If the sponsor or others share your information, your 
information may no longer be protected under the HIPAA Privacy Rule. 
How will my information be used? 
By signing this form, you are giving your permission to use and/or share your health information as 
described in this document for any and all study/research related purposes. Your authorization to use 
your health information will not expire unless you revoke it in writing. 
As part of this research, USF may collect, use, and share the following information: 
 Your current BMI, hemoglobin A1c (a measure of glycemic control), duration of diabetes, race, 
gender, and age 
 Levels of the inflammatory markers measured from your saliva 
 Your collected saliva sample may be used for future studies 
You can list any particular information that you do not want us to use or share in the space below. If 
you list nothing here, we can use and share all of the information listed above for this research but for 
nothing else. 
For the Research Participant (you) to complete: 
 I am asking USF and the researchers not to include, use, or share the following health information 
in this research (if blank, then no information will be excluded): 
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IRB Consent Rev. Date:2/20/2013 
Page 4 of 6 
Study ID:Ame2_Pro00009518 Date Approved: 2/25/2013 Expiration Date: 10/15/2013 
 
 
 
 
Your Rights: 
You can refuse to sign this form. If you do not sign this form you will not be able to take part in this 
research study and therefore not be able to receive the research related interventions. However, your 
health care outside of this study and benefits will not change. 
 
 
How Do I Withdraw Permission to Use My Information? 
You can revoke this form at any time by sending a letter clearly stating that you wish to withdraw your 
authorization to use of your health information in the research. If you revoke your permission: 
 You will no longer be a participant in this research study; 
 We will stop collecting new information about you; 
 We will use the information collected prior to the revocation of your authorization. This 
information may already have been used or shared with other, or we may need it to complete 
and protect the validity of the research; and 
 Staff may need to follow-up with you if there is a medical reason to do so. 
To revoke this form, please write to: 
Principal Investigator 
For IRB Study # Pro00009518 
University of South Florida 
College of Public Health, Department of Epidemiology and Biostatistics 
13201 Bruce B Downs Blvd, MDC 56 
Tampa, FL 33612 
While we are conducting the research study, we cannot let you see or copy the research information we 
have about you. After the research is completed, you have a right to see the information about you, as 
allowed by USF policies. 
 
Privacy and Confidentiality 
We will keep your study records private and confidential. Certain people may need to see your study 
records. By law, anyone who looks at your records must keep them completely confidential. The only 
people who will be allowed to see these records are: 
 The research team, including the Principal Investigator, study coordinator, research nurses, and 
all other research staff. 
 Certain government and university people who need to know more about the study. For 
example, individuals who provide oversight on this study may need to look at your records. 
This is done to make sure that we are doing the study in the right way. They also need to make 
sure that we are protecting your rights and your safety. 
 Any agency of the federal, state, or local government that regulates this research. This includes 
the Florida Department of Health, and the Department of Health and Human Services (DHHS) 
and the Office for Human Research Protection (OHRP). 
Study ID:Ame2_Pro00009518 Date Approved: 2/25/2013 Expiration Date: 10/15/2013 
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 The USF Institutional Review Board (IRB) and its related staff who have oversight 
responsibilities for this study, staff in the USF Office of Research and Innovation, USF 
Division of Research Integrity and Compliance, and other USF offices who oversee this 
research. 
We may publish what we learn from this study. If we do, we will not include your name. We will not 
publish anything that would let people know who you are. 
 
Voluntary Participation / Withdrawal 
You should only take part in this study if you want to volunteer. You should not feel that there is any 
pressure to take part in the study. You are free to participate in this research or withdraw at any time. 
There will be no penalty or loss of benefits you are entitled to receive if you stop taking part in this 
study. 
 
New information about the study 
During the course of this study, we may find more information that could be important to you. This 
includes information that, once learned, might cause you to change your mind about being in the study. 
We will notify you as soon as possible if such information becomes available. 
You can get the answers to your questions, concerns, or complaints 
If you have any questions, concerns or complaints about this study, or experience an adverse event or 
unanticipated problem, call Amy Alman at 813-974-2235. 
If you have questions about your rights as a participant in this study, general questions, or have 
complaints, concerns or issues you want to discuss with someone outside the research, call the USF 
IRB at (813) 974-5638. 
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Consent to Take Part in this Research Study 
and Authorization to Collect, Use and Share Your Health Information 
It is up to you to decide whether you want to take part in this study. If you want to take part, please 
sign the form, if the following statements are true. 
I freely give my consent to take part in this study and authorize that my health information as 
agreed above, be collected/disclosed in this study. I understand that by signing this form I am 
agreeing to take part in research. I have received a copy of this form to take with me. 
 
 
 
  
Signature of Person Taking Part in Study Date 
 
 
 
Printed Name of Person Taking Part in Study 
 
 
 
Statement of Person Obtaining Informed Consent 
I have carefully explained to the person taking part in the study what he or she can expect from their 
participation. I hereby certify that when this person signs this form, to the best of my knowledge, he/ 
she understands: 
 What the study is about; 
 What procedures/interventions/investigational drugs or devices will be used; 
 What the potential benefits might be; and 
 What the known risks might be. 
 
I can confirm that this research subject speaks the language that was used to explain this research and 
is receiving an informed consent form in the appropriate language. Additionally, this subject reads well 
enough to understand this document or, if not, this person is able to hear and understand when the form 
is read to him or her. This subject does not have a medical/psychological problem that would 
compromise comprehension and therefore makes it hard to understand what is being explained and 
can, therefore, give legally effective informed consent. This subject is not under any type of anesthesia 
or analgesic that may cloud their judgment or make it hard to understand what is being explained and, 
therefore, can be considered competent to give informed consent. 
 
 
  
Signature of Person Obtaining Informed Consent / Research Authorization Date 
 
 
 
Printed Name of Person Obtaining Informed Consent / Research Authorization 
Study ID:Ame2_Pro00009518 Date Approved: 2/25/2013 Expiration Date: 10/15/2013 
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Appendix C: Consent Form for Salivary Diurnal Inflammatory Study (SADI) 
 
Study ID:Pro00018592 Date Approved: 9/22/2015 Expiration Date: 9/22/2016 
Adult Minimal Risk 
Version Date: 09222015 
Version #  003 
Page 1 of 4 
 
 
 
 
 
 
 
Informed Consent to Participate in Research Involving Minimal Risk 
 
Pro # Pro00018592 
 
 
 
You are being asked to take part in a research study. Research studies include only people who choose 
to take part. This document is called an informed consent form. Please read this information carefully 
and take your time making your decision. Ask the researcher or study staff to discuss this consent form 
with you, please ask him/her to explain any words or information you do not clearly understand. 
 
We are asking you to take part in a research study called: 
Salivary Diurnal Inflammatory Study (SADI) 
The person who is in charge of this research study is Brant R. Burkhardt, Ph.D.. This person is called 
the Principal Investigator. However, other research staff may be involved and can act on behalf of the 
person in charge. 
The research will be conducted the University of South Florida USF Department of Cell Biology, 
Microbiology and Molecular Biology. 
 
 
 
Purpose of the study 
The purpose of this study is to: 
 Characterize inflammation in the saliva of healthy adults 
 Characterize the microbiome in the saliva of healthy adults 
Why are you being asked to take part? 
We are asking you to take part in this research study because you are in optimal health and have some 
degree of scientific training that enables you to understand and preserve self-collected saliva samples 
for subsequent analysis. 
 
Study Procedures: 
If you take part in this study, you will be asked to: 
 Provide saliva samples over the course of a day by passively drooling into a collection vial 
(instructions will be give upon consent) 
 Answer two questions about your oral health 
 Participation can take place at home 
 Your current BMI, race, gender, and age will be recorded for this study 
 We will not record your name, address, phone number, or any other identifying information 
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Study ID:Pro00018592 Date Approved: 9/22/2015 Expiration Date: 9/22/2016 
Adult Minimal Risk 
Version Date: 09222015 
Version #  003 
Page 2 of 4 
 
 
 
 
 
 
Total Number of Participants 
About 20 individuals will take part in this study at USF. 
 
Alternatives / Voluntary Participation / Withdrawal 
You do not have to participate in this research study. 
 
You should only take part in this study if you want to volunteer. You should not feel that there is any 
pressure to take part in the study. You are free to participate in this research or withdraw at any time. 
There will be no penalty or loss of benefits you are entitled to receive if you stop taking part in this 
study. Decision to not participate will not affect your student status (course grade) or job status. 
 
Benefits 
We are unsure if you will receive any benefits by taking part in this research study. 
 
Risks or Discomfort 
This research is considered to be minimal risk. That means that the risks associated with this study are 
the same as what you face every day. There are no known additional risks to those who take part in this 
study. 
 
Compensation 
You will receive no payment or other compensation for taking part in this study. 
 
Costs 
There will be no additional costs to you as a result of being in this study. 
 
Privacy and Confidentiality 
We will keep your study records private and confidential. Certain people may need to see your study 
records. Anyone who looks at your records must keep them confidential. These individuals include: 
 The research team, including the Principal Investigator, study coordinator, research nurses, 
and all other research staff. 
 Certain government and university people who need to know more about the study, and 
individuals who provide oversight to ensure that we are doing the study in the right way. 
 Any agency of the federal, state, or local government that regulates this research. 
 The USF Institutional Review Board (IRB) and related staff who have oversight 
responsibilities for this study, including staff in USF Research Integrity and Compliance. 
We may publish what we learn from this study. If we do, we will not include your name. We will not 
publish anything that would let people know who you are. 
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What if new information becomes available about the study? 
During the course of this study, we may find more information that could be important to you. This 
includes information that, once learned, might cause you to change your mind about being in this 
study. We will notify you as soon as possible if such information becomes available. 
 
 
You can get the answers to your questions, concerns, or complaints 
If you have any questions, concerns or complaints about this study, or experience an adverse event or 
unanticipated problem, call Brant Burkhardt at 813-974-5968. 
If you have questions about your rights as a participant in this study, or have complaints, concerns or 
issues you want to discuss with someone outside the research, call the USF IRB at (813) 974-5638. 
 
As part of this research, USF may collect, use, and share the following information 
 Your current BMI, race, gender, and age 
 Levels of the inflammatory markers measured from your saliva 
 Microbiome characterization 
 Your collected saliva sample may be used for future studies 
 
You can refuse to sign this form. If you do not sign this form you will not be able to take part 
in this research study. However, your care outside of this study  and  benefits  will  not change. 
Your authorization to use your health information will not expire unless you revoke (withdraw) 
it in writing. You can revoke this form at any time by sending a letter clearly stating that you wish 
to withdraw your authorization to use your health information in the research. If you revoke 
your permission: 
 You will no longer be a participant in this research study; 
 We will stop collecting new information about you; 
 We will use the information collected prior to the revocation of your authorization. This 
information may already have been used or shared with others, or we may need it to complete 
and protect the validity of the research; and 
 Staff may need to follow-up with you if there is a medical reason to do so. 
 In addition to the procedures outlined above, we are asking you to allow us to obtain and store 
samples of your saliva for use in future research. The samples will be stored in a locked -80°C 
freezer in tubes labeled only with subject number and no identifying information. 
 
To revoke this form, please write to: 
Brant Burkhardt, Ph.D. 
For IRB Study # Pro00018592 
University of South Florida 
4202 East Fowler Avenue 
Tampa, FL 33620-5550 
 
While we are conducting the research study, we cannot let you see or copy the research information we 
have about you. After the research is completed, you have a right to see the information about you, as 
allowed by USF policies. 
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Consent to Take Part in this Research Study 
I freely give my consent to take part in this study. I understand that by signing this form I am agreeing 
to take part in research. I have received a copy of this form to take with me. 
 
 
 
  
Signature of Person Taking Part in Study Date 
 
 
 
Printed Name of Person Taking Part in Study 
 
 
 
Statement of Person Obtaining Informed Consent 
I have carefully explained to the person taking part in the study what he or she can expect from their 
participation. I confirm that this research subject speaks the language that was used to explain this 
research and is receiving an informed consent form in their primary language. This research subject 
has provided legally effective informed consent. 
 
 
  
Signature of Person obtaining Informed Consent Date 
 
 
 
Printed Name of Person Obtaining Informed Consent 
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Appendix D: IRB Approval for Salivary Biomarkers of Inflammation in Type 1 Diabetes 
 
 
 
 
October 15, 2012 
 
Amy Alman, PhD 
Epidemiology and Biostatistics 
13201 Bruce B Downs Blvd., MDC 56 
Tampa, FL 33612 
 
RE:  Expedited Approval for Initial Review 
IRB#: Pro00009518 
Title:  Salivary biomarkers of inflammation in type 1 diabetes 
Dear Dr. Alman: 
On 10/15/2012 the Institutional Review Board (IRB) reviewed and APPROVED the above 
referenced protocol. Please note that your approval for this study will expire on 10/15/2013. 
 
Approved Items: 
Protocol Document(s): 
Salivary Biomarkers of Inflammation Protocol  
Salivary Biomarkers Abstraction Form 
 
Consent/Assent Documents: 
Revised Salivary inflammation Informed Consent.pdf 
 
Please note, the informed consent/assent documents are valid during the period indicated by the 
official, IRB-Approval stamp located on the form.  Valid consent must be documented on a copy 
of the most recently IRB-approved consent form. 
 
It was the determination of the IRB that your study qualified for expedited review which 
includes activities that (1) present no more than minimal risk to human subjects, and (2) involve 
only procedures listed in one or more of the categories outlined below. The IRB may review 
research through the expedited review procedure authorized by 45CFR46.110 and 21 CFR 
56.110. The research proposed in this study is categorized under the following expedited review 
categories 3, 5 and 7: 
 
(3) Prospective collection of biological specimens for research purposes by 
noninvasive means. 
 
(5) Research involving materials (data, documents, records, or specimens) that have 
been collected, or will be collected solely for nonresearch purposes (such as medical 
treatment or diagnosis). 
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(7) Research on individual or group characteristics or behavior (including, but not 
limited to, research on perception, cognition, motivation, identity, language, 
communication, cultural beliefs or practices, and social behavior) or research 
employing survey, interview, oral history, focus group, program evaluation, human 
factors evaluation, or quality assurance methodologies. 
 
As the principal investigator of this study, it is your responsibility to conduct this study in 
accordance with IRB policies and procedures and as approved by the IRB. Any changes to the 
approved research must be submitted to the IRB for review and approval by an amendment. 
 
We appreciate your dedication to the ethical conduct of human subject research at the University 
of South Florida and your continued commitment to human research protections.  If you have 
any questions regarding this matter, please call 813-974-5638. 
 
Sincerely, 
 
E. Verena Jorgensen, MD, Chairperson 
USF Institutional Review Board 
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Appendix E: IRB Approval for Salivary Diurnal Inflammatory Analysis 
 
 
 
 
9/22/2015 
 
Brant Burkhardt, Ph.D. 
Cellular, Molecular & Micro-Biology 
Tampa, FL 33620 
 
RE: Expedited Approval for Initial Review 
IRB#: Pro00018592 
Title: Salivary Diurnal Inflammatory Analysis (SADI) 
 
Study Approval Period: 9/22/2015 to 9/22/2016 
 
Dear Dr. Burkhardt: 
 
On 9/22/2015, the Institutional Review Board (IRB) reviewed and APPROVED the above 
application and all documents contained within, including those outlined below. 
 
Approved Item(s): 
Protocol Document(s): 
Salivary Diurnal Inflammatory Analysis (SADI) 
Salivary Inflammatory Manuscript 
 
Consent/Assent Document(s)*: 
SB Adult Minimal Risk_v003_biomed study_09222015.docx.pdf 
 
*Please use only the official IRB stamped informed consent/assent document(s) found under the 
"Attachments" tab. Please note, these consent/assent document(s) are only valid during the 
approval period indicated at the top of the form(s). 
 
It was the determination of the IRB that your study qualified for expedited review which 
includes activities that (1) present no more than minimal risk to human subjects, and (2) involve 
only procedures listed in one or more of the categories outlined below. The IRB may review 
research through the expedited review procedure authorized by 45CFR46.110 and 21 CFR 
56.110. The research proposed in this study is categorized under the following expedited review 
category: 
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(3) Prospective collection of biological specimens for research purposes by noninvasive means. 
 
(7) Research on individual or group characteristics or behavior (including, but not limited to, 
research on perception, cognition, motivation, identity, language, communication, cultural 
beliefs or practices, and social behavior) or research employing survey, interview, oral history, 
focus group, program evaluation, human factors evaluation, or quality assurance methodologies. 
 
As the principal investigator of this study, it is your responsibility to conduct this study in 
accordance with IRB policies and procedures and as approved by the IRB. Any changes to the 
approved research must be submitted to the IRB for review and approval via an amendment. 
Additionally, all unanticipated problems must be reported to the USF IRB within five (5) 
calendar days. 
 
We appreciate your dedication to the ethical conduct of human subject research at the University 
of South Florida and your continued commitment to human research protections.  If you have 
any questions regarding this matter, please call 813-974-5638. 
 
Sincerely, 
 
Janelle Perkins, Pharm.D., Chairperson 
USF Institutional Review Board 
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Appendix F: Interview and Abstraction Forms 
 
Salivary Biomarkers of Inflammation in Saliva 
Interview and Abstraction Form 
Version 08/16/2012 
 
Study ID:  ________ 
 
Oral Health Interview Questions 
1. Compared to others your age, how would you rate the condition of your gums? (Circle 
one) 
Excellent   Very Good  Good  Fair  Poor 
 
2. Do you have a loose tooth?  YES  NO 
 
Clinical Variables 
BMI  ______________ 
Race  ________________ 
Sex  ______________ 
Age  ______________ 
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Diurnal Rhythm of Salivary Biomarkers of Inflammation in Saliva 
Interview and Abstraction Form 
Version 05/20/2014 
 
Study ID:  ________ 
 
Oral Health Interview Questions 
1. Compared to others your age, how would you rate the condition of your gums? (Circle 
one) 
Excellent   Very Good  Good  Fair  Poor 
 
2. Do you have a loose tooth?  YES  NO 
 
Clinical Variables 
BMI  ______________ 
Race  ________________ 
Sex  ______________ 
Age  ______________ 
